Clinical & Payment Policies
Clinical Policies
Clinical policies are one set of guidelines used to assist in administering health plan benefits, either by prior authorization or payment rules. They include but are not limited to policies relating to evolving medical technologies and procedures, as well as pharmacy policies. Clinical policies help identify whether services are medically necessary based on information found in generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by the policy; and other available clinical information.
All policies found in the Coordinated Care Clinical Policy Manual apply to Coordinated Care members. Policies in the Coordinated Care Clinical Policy Manual may have either a Coordinated Care or a “Centene” heading. Coordinated Care utilizes InterQual® criteria for those medical technologies, procedures or pharmaceutical treatments for which a Coordinated Care clinical policy does not exist. InterQual is a nationally recognized evidence-based decision support tool. You may access the InterQual® SmartSheet(s)™ for Adult and Pediatric procedures, durable medical equipment and imaging procedures by logging into the secure provider portal or by calling Coordinated Care. In addition, Coordinated Care may from time to time delegate utilization management of specific services; in such circumstances, the delegated vendor’s guidelines may also be used to support medical necessity and other coverage determinations. Other non-clinical policies (e.g., payment policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Clinical Policy Manuals or InterQual®criteria is payable by Coordinated Care.
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
Ambetter Clinical Policies Listing
For Ambetter information, please visit our Ambetter from Coordinated Care website.
Ambetter Pharmacy Policies Listing
- Abaloparatide (Tymlos) (PDF) (CP.PHAR.345)
- Abametapir (Xeglyze) (PDF) (CP.PMN.253)
- Abemaciclib (Verzenio) (PDF) (CP.PHAR.355)
- Abrocitinib (Cibinqo) (PDF) (CP.PHAR.578)
- Acalabrutinib (Calquence) (PDF) (CP.PHAR.366)
- Acyclovir Buccal Tablet (Sitavig), Ophthalmic Ointment (Avaclyr) (PDF) (CP.PMN.210)
- Adzynma (ADAMTS13, Recombinant-krhn) (PDF) (CP.PHAR.635)
- Afamelanotide (Scenesse) (PDF) (CP.PHAR.444)
- Abiraterone (PDF) (CP.PHAR.84)
- AbobotulinumtoxinA (Dysport) (PDF) (CP.PHAR.230)
- Adagrasib (Krazati) (PDF) (CP.PHAR.605)
- Adefovir (Hepsera) (PDF) (CP.PHAR.142)
- Ado-Trastuzumab (Kadcyla) (PDF) (CP.PHAR.229)
- Aducanumab (PDF) (CP.PHAR.468)
- Afatinib (Gilotrif) (PDF) (CP.PHAR.298)
- Afinitor (everolimus) (PDF) (CP.PHAR.63)
- Aflibercept (Eylea, Eylea HD), Aflibercept-yszy (Opuviz), Aflibercept-jbvf (Yesafili), Aflibercept-mrbb (Ahzantive) (PDF) (CP.PHAR.184)
- Agalsidase Beta (Fabrazyme) (PDF) (CP.PHAR.158)
- Age Limit Override (Codeine, Tramadol, Hydrocodone) (PDF) (CP.PMN.138)
- Alectinib (Alecensa) (PDF) (CP.PHAR.369)
- Alemtuzumab (Lemtrada) (PDF) (CP.PHAR.243)
- Alendronate (Binosto, Fosamax plus D) (PDF) (CP.PMN.88)
- Alglucosidase (Lumizyme) (PDF) (CP.PHAR.160)
- Allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen-dsat (StrataGraft) (PDF) (CP.PHAR.562)
- Allogenic Processed Thymus Tissue-agdc (Rethymic) (PDF) (CP.PHAR.563)
- Alpelisib (Piqray) (PDF) (CP.PHAR.430)
- Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) (PDF) (CP.PHAR.94)
- Amantadine ER (Gocovri, Osmolex ER) (PDF) (CP.PMN.89)
- Ambrisentan (Letairis®) (PDF) (CP.PHAR.190)
- Amifampridine (Firdapse) (PDF) (CP.PHAR.411)
- Amikacin (Arikayce) (PDF) (CP.PHAR.401)
- Amisulpride (Barhemsys) (PDF) (CP.PMN.236)
- Amivantamab-vmjw (Rybrevant) (PDF) (CP.PHAR.544)
- Anifrolumab-fnia (Saphnelo) (PDF) (CP.PHAR.551)
- Anti-Inhibitor Coagulant Complex (Feiba®) (PDF) (CP.PHAR.217)
- Antithrombin III (ATryn, Thrombate III) (PDF) (CP.PHAR.564)
- Antithymocyte Globulin (Atgam, Thymoglobulin) (PDF) (CP.PHAR.506)
- Apalutamide (Erleada) (PDF) (CP.PCH.45)
- Apomorphine (Apokyn, Kynmobi) (PDF) (CP.PHAR.488)
- aprepitant (PDF) (CP.PMN.19)
- Aprocitentan (Tryvio) (PDF) (CP.PHAR.676)
- Aripiprazole Long-Acting Injections (Abilify Maintena, Aristada) (PDF) (CP.PHAR.290)
- Aripiprazole Orally Disintegrating Tablet (PDF) (CP.PCH.37)
- Armodafinil (Nuvigil) (PDF) (CP.PMN.35)
- Asciminib (Scemblix) (PDF) (CP.PHAR.565)
- Asenapine (Saphris, Secuado) (PDF) (CP.PMN.15)
- Asfotase Alfa (Strensiq) (PDF) (CP.PHAR.328)
- Aspirin-dipyridamole (Aggrenox) (PDF) (CP.PMN.20)
- Atezolizumab (Tecentriq®) (PDF) (CP.PHAR.235)
- Atidarsagene Autotemcel (Lenmeldy) (PDF) (CP.PHAR.602)
- Atogepant (Qulipta) (PDF) (CP.PHAR.566)
- Avacincaptad pegol (Izervay) (PDF) (CP.PHAR.641)
- Avacopan (Tavneos) (PDF) (CP.PHAR.515)
- Avalglucosidase Alfa-ngpt (Nexviazyme) (PDF) (CP.PHAR.521)
- Avapritinib (Ayvakit) (PDF) (CP.PHAR.454)
- Avatrombopag (Doptelet) (PDF) (CP.PHAR.130)
- Avelumab (Bavencio®) (PDF) (CP.PHAR.333)
- Axicabtagene Ciloleucel (Yescarta®) (PDF) (CP.PHAR.362)
- Axitinib (Inlyta®) (PDF) (CP.PHAR.100)
- Azacitidine (Vidaza) (PDF) (CP.PHAR.387)
- Azelaic Acid (Finacea) (PDF) (HIM.PA.119)
- Aztreonam (Cayston®) (PDF) (CP.PHAR.209)
- Baloxavir Marboxil (Xofluza) (PDF) (CP.PMN.185)
- Bedaquiline (Sirturo) (PDF) (CP.PMN.212)
- Belantamab Mafodotin (Blenrep) (PDF) (CP.PHAR.469)
- belatacept (Nulojix®) (PDF) (CP.PHAR.201)
- Belimumab (Benlysta) (PDF) (CP.PHAR.88)
- belinostat (Beleodaq®) (PDF) (CP.PHAR.311)
- Belumosudil (Rezurock) (PDF) (CP.PHAR.552)
- Belzutifan (Welireg) (PDF) (CP.PHAR.553)
- Bempedoic Acid (Nexletol), Bempedoic Acid/Ezetimibe (Nexlizet) (PDF) (CP.PMN.237)
- bendamustine (Bendeka®, Treanda®) (PDF) (CP.PHAR.307)
- Benralizumab (Fasenra) (PDF) (CP.PHAR.373)
- Benznidazole (PDF) (CP.PMN.90)
- Berdazimer (Zelsuvmi) (PDF) (CP.PMN.293)
- Beremagene geperpavec-svdt (Vyjuvek) (PDF) (CP.PHAR.592)
- Berotralstat (Orladeyo) (PDF) (HIM.PA.169)
- Betaine (Cystadane) (PDF) (CP.PHAR.143)
- Betamethasone Dipropionate Spray (Sernivo) (PDF) (CP.PMN.182)
- Betibeglogene Autotemcel (Zynteglo) (PDF) (CP.PHAR.545)
- Bevacizumab (Avastin) (PDF) (CP.PHAR.93)
- Bexarotene (Targretin Capsules, Gel) (PDF) (CP.PHAR.75)
- Bezlotoxumab (Zinplava) (PDF) (CP.PHAR.300)
- Bimatoprost Implant (Durysta) (PDF) (CP.PHAR.486)
- Binimetinib (PDF) (CP.PHAR.50)
- Biologic DMARDs (PDF) (HIM.PA.SP60)
- Birch Triterpenes (Filsuvez) (PDF) (CP.PHAR.669)
- Blinatumomab (PDF) (CP.PHAR.312)
- Bortezomib (Velcade) (PDF) (CP.PHAR.410)
- Bosentan (Tracleer®) (PDF) (CP.PHAR.191)
- Bosutinib (Bosulif) (PDF) (CP.PHAR.105)
- Brand Name Override and Non-Formulary Medications (PDF) (HIM.PA.103)
- Brentuximab (PDF) (CP.PHAR.303)
- Brexanolone (Zulresso) (PDF) (CP.PHAR.417)
- Brexpiprazole (Rexulti) (PDF) (CP.PMN.68)
- Brexucabtagene Autoleucel (Tecartus) (PDF) (CP.PHAR.472)
- Brigatinib (Alunbrig) (PDF) (CP.PHAR.342)
- Brimonidine Tartrate (Mirvaso) (PDF) (CP.PMN.192)
- Brinzolamide/Brimonidine (Simbrinza) (PDF) (HIM.PA.15)
- Brivaracetam (Briviact) (PDF) (CP.PCH.26)
- Brolucizumab-dbll (Beovu) (PDF) (CP.PHAR.445)
- Budesonide (Eohilia, Uceris) (PDF) (CP.PMN.294)
- Budesonide (Tarpeyo) (PDF) (CP.PHAR.572)
- Buprenorphine (Subutex) (PDF) (CP.PMN.82)
- buprenorphine implant (Probuphine) (PDF) (CP.PHAR.289)
- Buprenorphine-Naloxone (Bunavail, Cassipa, Suboxone, Zubsolv) (PDF) (CP.PMN.81)
- Bupropion/Naltrexone (Contrave) (PDF) (CP.PCH.12)
- Burosumab-twza (Crysvita) (PDF) (CP.PHAR.11)
- Butorphanol Nasal Spray (PDF) (HIM.PA.46)
- C1 Esterase Inhibitors (Berinert, Cinryze, Haegarda, Ruconest) (PDF) (HIM.PA.170)
- Cabazitaxel (Jevtana) (PDF) (CP.PHAR.316)
- Cabotegravir (Apretude), Cabotegravir/Rilpivirine (Cabenuva) (PDF) (CP.PHAR.573)
- Cabozantinib (Cometriq®, Cabometyx®) (PDF) (CP.PHAR.111)
- Calcifediol (Rayaldee) (PDF) (CP.PMN.76)
- Calcipotriene/Betamethasone Dipropionate Foam (Enstilar) (PDF) (CP.PMN.181)
- Canakinumab (Ilaris) (PDF) (CP.PHAR.246)
- Cannabidiol (Epidiolex) (PDF) (CP.PMN.164)
- Capecitabine (Xeloda) (PDF) (CP.PHAR.60)
- Capivasertib (Truqap) (PDF) (CP.PHAR.663)
- Caplacizumab-yhdp (Cablivi) (PDF) (CP.PHAR.416)
- Capmatinib (Tabrecta) (PDF) (CP.PHAR.494)
- Carbidopa/Levodopa ER Capsules (Rytary), Enteral Suspension (Duopa), IR Tablets (Dhivy) (PDF) (CP.PMN.238)
- carfilzomib (Kyprolis®) (PDF) (CP.PHAR.309)
- Carglumic Acid (Carbaglu) (PDF) (CP.PHAR.206)
- Cariprazine (Vraylar) (PDF) (CP.PMN.91)
- Casimersen (Amondys 45) (PDF) (CP.PHAR.470)
- Casirivimab and Imdevimab (REGEN-COV) (PDF) (CP.PHAR.520)
- Celecoxib (Celebrex) (PDF) (CP.PMN.122)
- Cemiplimab-rwlc (Libtayo) (PDF) (CP.PHAR.397)
- Cenegermin-bkbj (Oxervate) (PDF) (CP.PMN.186)
- Cenobamate (Xcopri) (PDF) (CP.PMN.231)
- Ceritinib (Zykadia) (PDF) (CP.PHAR.349)
- Cerliponase alfa (PDF) (CP.PHAR.338)
- cetuximab (Erbitux®) (PDF) (CP.PHAR.317)
- Chenodiol (Chenodal) (PDF) (CP.PMN.239)
- Chlorambucil (Leukeran) (PDF) (CP.PHAR.554)
- Chloramphenicol Sodium Succinate (PDF) (CP.PHAR.388)
- Cholic Acid (Cholbam) (PDF) (CP.PHAR.390)
- Ciclopirox (Penlac) (PDF) (CP.PMN.24)
- Ciltacabtagene Autoleucel (Carvykti) (PDF) (CP.PHAR.533)
- Cipaglucosidase Alfa-atga + Miglustat (Pombiliti + Opfolda) (PDF) (CP.PHAR.567)
- Ciprofloxacin-Dexamethasone (Ciprodex) (PDF) (CP.PMN.248)
- Ciprofloxacin/Fluocinolone (Otovel) (PDF) (CP.PMN.249)
- Cladribine (Mavenclad) (PDF) (CP.PHAR.422)
- Clascoterone (Winlevi) (PDF) (CP.PMN.257)
- Clobazam (PDF) (CP.PMN.54)
- CNS Stimulants (PDF) (CP.PMN.92)
- Cobimetinib (Cotellic) (PDF) (CP.PHAR.380)
- Colchicine (Colcrys, Lodoco) (PDF) (CP.PMN.123)
- Colesevelam (Welchol) (PDF) (CP.PMN.250)
- Collagenase (PDF) (CP.PHAR.82)
- Colonoscopy Preparation Products (PDF) (CP.PCH.43)
- Compounded Medications (PDF) (CP.PMN.280)
- Conjugated Estrogens/Bazedoxifene (Duavee) (PDF) (CP.PMN.258)
- copanlisib (Aliqopa®) (PDF) (CP.PHAR.357)
- Corticosteroids for Ophthalmic Injection (Dextenza, Iluvien, Ozurdex, Retisert, Xipere, Yutiq) (PDF) (CP.PHAR.385)
- Cosyntropin (Cortrosyn®) (PDF) (CP.PHAR.203)
- Crisaborole (Eucrisa) (PDF) (CP.PMN.110)
- Crizanlizumab-tmca (Adakveo) (PDF) (CP.PHAR.449)
- Crizotinib (Xalkori) (PDF) (CP.PHAR.90)
- Crovalimab-akkz (PiaSky) (PDF) (CP.PHAR.664)
- Cyclosporine ophthalmic emulsion (Cequa, Restasis) (PDF) (CP.PMN.48)
- Cyramza® (PDF) (CP.PHAR.119)
- Cysteamine ophthalmic (Cystaran, Cystadrops) (PDF) (CP.PMN.130)
- Cysteamine oral (Cystagon, Procysbi) (PDF) (CP.PHAR.155)
- Cytomegalovirus Immune Globulin (Cytogam) (PDF) (CP.PHAR.277)
- Dabrafenib (Tafinlar) (PDF) (CP.PHAR.239)
- Dacomitinib (Vizimpro) (PDF) (CP.PHAR.399)
- Dalfampridine (Ampyra) (PDF) (CP.PHAR.248)
- Dalteparin (Fragmin) (PDF) (CP.PHAR.225)
- Danicopan (Voydeya) (PDF) (CP.PHAR.665)
- Daptomycin (Cubicin, Cubicin RF) (PDF) (CP.PHAR.351)
- Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro) (PDF) (CP.PHAR.310)
- Darbepoetin alfa (Aranesp) (PDF) (CP.PHAR.236)
- Darolutamide (Nubeqa) (PDF) (CP.PHAR.435)
- Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira Pak) (PDF) (HIM.PA.SP61)
- Dasatinib (Sprycel) (PDF) (CP.PHAR.72)
- Daprodustat (Jesduvroq) (PDF) (CP.PHAR.628)
- Dapsone (Aczone Gel) (PDF) (CP.PCH.32)
- daunorubicin/cytarabine (Vyxeos®) (PDF) (CP.PHAR.352)
- DaxibotulinumtoxinA-lanm (Daxxify) (PDF) (CP.PHAR.651)
- Decitabine-Cedazuridine (Inqovi) (PDF) (CP.PHAR.479)
- deferasirox (PDF) (CP.PHAR.145)
- Deferoxamine (Desferal) (PDF) (CP.PHAR.146)
- Deflazacort (Emflaza) (PDF) (CP.PHAR.331)
- degarelix acetate (Firmagon®) (PDF) (CP.PHAR.170)
- Delafloxacin (Baxdela) (PDF) (CP.PMN.115)
- Delandistrogene moxeparvovec-rokl (Elevidys) (PDF) (CP.PHAR.593)
- Denosumab (Prolia, Xgeva), Denosumab-bbdz (Jubbonti, Wyost) (PDF) (CP.PHAR.58)
- Desmopressin Acetate (DDAVP, Stimate, Nocdurna, Noctiva) (PDF) (CP.PHAR.214)
- Deutetrabenazine (Austedo) (PDF) (CP.PCH.42)
- Dexrazoxane (Zinecard Totect) (PDF) (CP.PHAR.418)
- Dextromethorphan/Bupropion (Auvelity) (PDF) (CP.PMN.284)
- Dextromethorphan-Quinidine (Nuedexta) (PDF) (CP.PMN.93)
- Diazepam Nasal Spray (Valtoco) (PDF) (CP.PMN.216)
- Dichlorphenamide (Keveyis) (PDF) (CP.PMN.261)
- Diclofenac (Cambia, Flector, Licart, Pennsaid, Solaraze, Zipsor, Zorvolex) (PDF) (CP.PCH.28)
- Dimethyl Fumarate (Tecfidera), Diroximel Fumarate (Vumerity), Monomethyl Fumarate (Bafiertam) (PDF) (CP.PHAR.249)
- Dipeptidyl Peptidase-4 Inhibitors (PDF) (HIM.PA.58)
- Dolasetron (Anzemet) (PDF) (CP.PMN.141)
- Donanemab (Kinsunla) (PDF) (CP.PHAR.594)
- Dornase alfa (Pulmozyme) (PDF) (CP.PHAR.212)
- Dostarlimab-gxly (Jemperli) (PDF) (CP.PHAR.540)
- Doxepin Hydrochloride Cream (Prudoxin, Zonalon) (PDF) (HIM.PA.147)
- Doxycycline Hyclate (Acticlate, Doryx), Doxycycline (Oracea) (PDF) (CP.PMN.79)
- Dupilumab (Dupixent) (PDF) (HIM.PA.SP69)
- Durvalumab (Imfinzi) (PDF) (CP.PHAR.339)
- Dutasteride (Avodart), Dutasteride/Tamsulosin (Jalyn) (PDF) (CP.PMN.128)
- Duvelisib (Copiktra) (PDF) (CP.PHAR.400)
- Ecallantide (Kalbitor®) (PDF) (CP.PHAR.177)
- Eculizumab (Soliris®) (CP.PHAR.97)
- Edaravone (Radicava) (PDF) (CP.PHAR.343)
- Efgartigimod Alfa-fcab (Vyvgart) (PDF) (CP.PHAR.555)
- Efinaconazole (Jublia) (PDF) (CP.PMN.25)
- Eflornithine (Iwilfin) (PDF) (CP.PHAR.670)
- Elacestrant (Orserdu) (PDF) (CP.PHAR.623)
- Elafibranor (Iqirvo) (PDF) (CP.PHAR.688)
- Elagolix (Orilissa) (PDF) (CP.PHAR.136)
- Elapegademase-lvlr (Revcovi) (PDF) (CP.PHAR.419)
- Elbasvir/Grazoprevir (Zepatier) (PDF) (HIM.PA.SP62)
- Electromyography and Nerve Conduction Studies (PDF) (CP.MP.211) Effective 9/1/21
- Elexacaftor, tezacaftor (Trikafta) (PDF) (CP.PHAR.440)
- Eliglustat (Cerdelga) (PDF) (CP.PHAR.153)
- Elivaldogene Autotemcel (Skysona) (PDF) (CP.PHAR.556)
- Elotuzumab (Empliciti®) (PDF) (CP.PHAR.308)
- Elosulfase alfa (Vimizim) (PDF) (CP.PHAR.162)
- Elranatamab-bcmm (Elrexfio) (PDF) (CP.PHAR.652)
- Eltrombopag (Promacta®) (PDF) (CP.PHAR.180)
- Eluxadoline (Viberzi) (PDF) (CP.PMN.170)
- Emapalumab-lzsg (Gamifant) (PDF) (CP.PHAR.402)
- Emicizumab-kxwh (Hemlibra) (PDF) (CP.PHAR.370)
- Emtricitabine/Tenofovir Alafenamide (Descovy) (PDF) (CP.PMN.235)
- Enasidenib (Idhifa) (PDF) (CP.PHAR.363)
- Encorafenib (PDF) (CP.PHAR.127)
- Enfortumab Vedotin-ejfv (Padcev) (PDF) (CP.PHAR.455)
- Enfuvirtide (PDF) (CP.PHAR.41)
- Enoxaparin (Lovenox) (PDF) (CP.PHAR.224)
- Entecavir (Baraclude) (PDF) (HIM.PA.08)
- Entrectinib (Rozlytrek) (PDF) (CP.PHAR.441)
- Enzalutamide (Xtandi) (PDF) (CP.PHAR.106)
- Epcoritamab-bysp (Epkinly) (PDF) (CP.PHAR.634)
- Eplontersen (Wainua) (PDF) (CP.PHAR.633)
- Epoetin alfa (Epogen, Procrit), Epoetin alfa-epbx (Retacrit) (PDF) (CP.PHAR.237)
- Epoprostenol (Flolan®, Veletri®) (PDF) (CP.PHAR.192)
- Eptinezumab-jjmr (Vyepti) (PDF) (HIM.PA.SP64)
- Erdafitinib (Balversa) (PDF) (CP.PHAR.423)
- Eribulin Mesylate (Halaven®) (PDF) (CP.PHAR.318)
- Erlotinib (Tarceva) (PDF) (CP.PHAR.74)
- Erenumab-aaoe (Aimovig) (PDF) (HIM.PA.SP65)
- erwina asparaginase (Erwinaze®) (PDF) (CP.PHAR.301)
- Esketamine (Spravato) (PDF) (CP.PMN.199)
- Estradiol Vaginal Ring (Femring) (PDF) (CP.PMN.263)
- Etelcalcetide (Parsabiv) (PDF) (CP.PHAR.379)
- Eteplirsen (Exondys 51) (PDF) (CP.PHAR.288)
- Etranacogene Dezaparvovec-drlb (Hemgenix) (PDF) (CP.PHAR.580)
- Evinacumab-dgnb (Evkeeza) (PDF) (HIM.PA.166)
- Evolocumab (Repatha) (PDF) (HIM.PA.156)
- Exagamglogene Autotemcel (Casgevy) (PDF) (CP.PHAR.603)
- Factor IX (Human, Recombinant) (PDF) (CP.PHAR.218)
- Factor IX Complex Human (Bebulin®, Profilnine®) (PDF) (CP.PHAR.219)
- Factor VIIa, Recombinant (NovoSeven® RT) (PDF) (CP.PHAR.220)
- Factor VIII (Human Recombinant) (PDF) (CP.PHAR.215)
- Factor VIII/von Willebrand Factor Complex (Human - Alphanate®, Humate-P®, Wilate®) (PDF) (CP.PHAR.216)
- Factor XIII A-Subunit, Recombinant (Tretten®) (PDF) (CP.PHAR.222)
- Factor XIII, Human (Corifact®) (PDF) (CP.PHAR.221)
- Fam-trastuzumab Deruxtecan-nxki (Enhertu) (PDF) (CP.PHAR.456)
- Faricimab-svoa (Vabysmo) (PDF) (CP.PHAR.581)
- Febuxostat (Uloric) (PDF) (CP.PMN.57)
- Fecal Microbiota, Live-jslm (Rebyota) (PDF) (CP.PHAR.613)
- Fecal Microbiota Spores, Live-brpk (Vowst) (PDF) (CP.PHAR.632)
- Fedratinib (Inrebic) (PDF) (CP.PHAR.442)
- Fenfluramine (Fintepla) (PDF) (CP.PMN.246)
- Fentanyl IR (Abstral, Actiq, Fentora, Lazanda, Subsys) (PDF) (CP.PMN.127)
- Ferric Carboxymaltose (Injectafer) (PDF) (CP.PHAR.234)
- Ferric Derisomaltose (Monoferric) (PDF) (CP.PHAR.480)
- Ferric gluconate (Ferrlecit®) (PDF) (CP.PHAR.166)
- Ferric Maltol (Accrufer) (PDF) (CP.PMN.213)
- Ferric Pyrophosphate (Triferic, Triferic Avnu) (PDF) (CP.PHAR.624)
- Ferumoxytol (Feraheme®) (PDF) (CP.PHAR.165)
- Fezolinetant (Veozah) (PDF) (CP.PMN.289)
- Fibrinogen Concentrate [Human] (Fibryga, RiaSTAP) (PDF) (CP.PHAR.526)
- Fidanacogene Elaparvovec-dzkt (Beqvez) (PDF) (CP.PHAR.643)
- Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix), Filgrastim-aafi (Nivestym), Filgrastim-ayow (Releuko), Filgrastim-txid (Nypozi) (PDF) (CP.PHAR.297)
- Finerenone (Kerendia) (PDF) (CP.PMN.266)
- Fingolimod (Gilenya) (PDF) (CP.PCH.38)
- Flibanserin (Addyi) (PDF) (CP.PHAR.446)
- Fluorouracil Cream (Tolak) (PDF) (CP.PMN.165)
- Fluticasone Propionate (Xhance) (PDF) (CP.PMN.95)
- Fondaparinux (Arixtra) (PDF) (CP.PHAR.226)
- Formulary Medications Without Specific Guidelines (PDF) (HIM.PA.33)
- Fosdenopterin (Nulibry) (PDF) (CP.PHAR.471)
- Fostamatinib (Tavalisse) (PDF) (CP.PHAR.24)
- Fremanezumab-vfrm (Ajovy) (PDF) (HIM.PA.SP66)
- Fruquintinib (Fruzaqla) (PDF) (CP.PHAR.666)
- Fulvestrant (Faslodex Injection) (PDF) (CP.PHAR.424)
- Furosemide (Furoscix) (PDF) (CP.PHAR.608)
- Futibatinib (Lytgobi) (PDF) (CP.PHAR.604)
- Gabapentin ER (Gralise, Horizant) (PDF) (CP.PMN.240)
- Galcanezumab-gnlm (Emgality) (PDF) (HIM.PA.SP67)
- Galsulfase (Naglazyme) (PDF) (CP.PHAR.161)
- Ganaxolone (Ztalmy) (PDF) (CP.PMN.278)
- Gefitinib (Iressa) (PDF) (CP.PHAR.68)
- gemtuzumab ozogamicin (Mylotarg®) (PDF) (CP.PHAR.358)
- Gender Affirming Treatments for Specialist Review (PDF) (WA.PHAR.142)
- Gepirone (Exxua) (PDF) (CP.PMN.292)
- Gilteritinib (Xospata) (PDF) (CP.PHAR.412)
- Givinostat (Duvyzat) (PDF) (CP.PHAR.644)
- Givosiran (Givlaari) (PDF) (CP.PHAR.457)
- Glasdegib (Daurismo) (PDF) (CP.PHAR.413)
- Glatiramer Acetate (Copaxone, Glatopa) (PDF) (CP.PHAR.252)
- Glaucoma Agents (PDF) (CP.PMN.286)
- Glecaprevir/Pibrentasvir (Mavyret) (PDF) (HIM.PA.SP36)
- Glofitamab-gxbm (Columvi) (PDF) (CP.PHAR.636)
- Glucagon-Like Peptide-1 Receptor Agonists (PDF) (HIM.PA.53)
- Glycerol phenylbutyrate (Ravicti®) (PDF) (CP.PHAR.207)
- Golodirsen (Vyondys 53) (PDF) (CP.PHAR.453)
- goserelin acetate (Zoladex®) (PDF) (CP.PHAR.171)
- Granisetron (Sancuso, Sustol) (PDF) (CP.PMN.74)
- Halcinonide (Halog) (PDF) (HIM.PA.20)
- Halobetasol Propionate (Bryhali, Lexette, Ultravate) (PDF) (CP.PMN.180)
- Halobetasol Propionate/Tazarotene (Duobrii) (PDF) (CP.PMN.208)
- Hemin (Panhematin®) (PDF) (CP.PHAR.181)
- histrelin acetate (Vantas®, Supprelin LA®) (PDF) (CP.PHAR.172)
- House Dust Mite Allergen Extract (Odactra) (PDF) (CP.PMN.111)
- Human Growth Hormone (Somapacitan, Somatropin) (PDF) (HIM.PA.161)
- Hyaluronate Derivatives (PDF) (CP.PHAR.05)
- Hydroxyprogesterone Caproate (Makena/compound) (PDF) (CP.PHAR.14)
- Hydroxyurea (Siklos) (PDF) (CP.PMN.193)
- Ibalizumab-uiyk (Trogarzo) (PDF) (CP.PHAR.378)
- Ibandronate Injection (Boniva) (PDF) (CP.PHAR.189)
- Ibrutinib (PDF) (CP.PHAR.126)
- Ibuprofen/Famotidine (Duexis) (PDF) (CP.PMN.120)
- Icatibant (Firazyr®) (PDF) (CP.PHAR.178)
- Icosapent ethyl (Vascepa) (PDF) (CP.PMN.187)
- Idecabtagene Vicleucel (Abecma) (PDF) (CP.PHAR.481)
- Idelalisib (Zydelig) (PDF) (CP.PHAR.133)
- Idursulfase (PDF) (CP.PHAR.156)
- Iloperidone (Fanapt) (PDF) (CP.PMN.32)
- Iloprost (Ventavis®) (PDF) (CP.PHAR.193)
- Imatinib (Gleevec) (CP.PHAR.65) (PDF)
- Imetelstat (Rytelo) (PDF) (CP.PHAR.690)
- Imiglucerase (Cerezyme) (PDF) (CP.PHAR.154)
- Immune Globulins (PDF) (CP.PHAR.103)
- Inclisiran (Leqvio) (PDF) (CP.PHAR.568)
- IncobotulinumtoxinA (Xeomin) (PDF) (CP.PHAR.231)
- Inebilizumab-cdon (Uplizna) (PDF) (CP.PHAR.458)
- Inhaled Agents for Asthma and COPD (PDF) (HIM.PA.153)
- Infertility and Fertility Preservation (PDF) (CP.PHAR.131)
- Infigratinib (Truseltiq) (PDF) (CP.PHAR.547)
- Inotersen (Tegsedi) (PDF) (CP.PHAR.405)
- inotuzumab ozogamicin (Besponsa®) (PDF) (CP.PHAR.359)
- Insulin Degludec (Tresiba) (PDF) (HIM.PA.09)
- Insulin detemir (Levemir) (PDF) (HIM.PA.171)
- Insulin Delivery Systems (V-Go, Omnipod, InPen) (PDF) (CP.PHAR.534)
- Interferon beta-1a (Avonex, Rebif) (PDF) (CP.PHAR.255)
- Interferon Beta-1b (Betaseron, Extavia) (PDF) (CP.PCH.46)
- Interferon Gamma- 1b (Actimmune) (PDF) (CP.PHAR.52)
- Intrathecal Baclofen (Gablofen, Lioresal) (PDF) (CP.PHAR.149)
- Iobenguane I-131 (Azedra) (PDF) (CP.PHAR.459)
- Ipilimumab (Yervoy) (PDF) (CP.PHAR.319)
- Iptacopan (Fabhalta) (PDF) (CP.PHAR.656)
- irinotecan Liposome (Onivyde®) (PDF) (CP.PHAR.304)
- Iron sucrose (Venofer®) (PDF) (CP.PHAR.167)
- Isatuximab-irfc (Sarclisa) (PDF) (CP.PHAR.482)
- Isavuconazonium (Cresemba®) (PDF) (CP.PMN.154)
- Isotretinoin (PDF) (CP.PMN.143)
- Istradefylline (Nourianz) (PDF) (CP.PMN.217)
- Itraconazole (Sporanox, Onmel) (PDF) (CP.PMN.124)
- Ivabradine (Corlanor) (PDF) (CP.PMN.70)
- Ivacaftor (Kalydeco) (PDF) (CP.PHAR.210)
- ivermectin (Sklice®) (PDF) (HIM.PA.124)
- Ivermectin (Stromectol, Sklice) (PDF) (CP.PMN.269)
- Ivosidenib (Tibsovo) (PDF) (CP.PHAR.137)
- Ixazomib (PDF) (CP.PHAR.302)
- Ketamine (Ketalar) (PDF) (CP.PMN.296)
- Ketorolac Nasal Spray (Sprix) (PDF) (CP.PMN.282)
- Korlym (mifepristone) (PDF) (CP.PHAR.101)
- Lanadelumab-fylo (Takhzyro) (PDF) (HIM.PA.172)
- Lanreotide (Somatuline Depot) (PDF) (CP.PHAR.391)
- lapatinib (Tykerb®) (PDF) (CP.PHAR.79)
- Laronidase (Aldurazyme) (PDF) (CP.PHAR.152)
- Larotrectinib (Vitrakvi) (PDF) (CP.PHAR.414)
- Lasmiditan (Reyvow) (PDF) (CP.PMN.218)
- Lecanemab-irmb (Leqembi) (PDF) (CP.PHAR.596)
- Ledipasvir/Sofosbuvir (Harvoni) (PDF) (HIM.PA.SP3)
- Lefamulin (Xenleta) (PDF) (CP.PMN.219)
- Lenacapavir (Sunlenca) (PDF) (CP.PHAR.622)
- Lenalidomide (Revlimid) (PDF) (CP.PHAR.71)
- Leniolisib (Joenja) (PDF) (CP.PHAR.597)
- Lenvatinib (Lenvima) (PDF) (CP.PHAR.138)
- Letermovir (Prevymis) (PDF) (CP.PHAR.367)
- Levodopa Inhalation Powder (Inbrija) (PDF) (CP.PMN.267)
- Levoketoconazole (Recorlev) (PDF) (CP.PMN.275)
- levoleucovorin (Fusilev) (PDF) (CP.PHAR.151)
- Levomilnacipran (Fetzima) (PDF) (HIM.PA.125)
- Leucovorin Injection (PDF) (CP.PHAR.393)
- Leuprolide Acetate (Lupron, Lupron Depot, Eligard, Lupaneta Pack, Fensolvi) (PDF) (CP.PHAR.173)
- L-glutamine (Endari) (PDF) (CP.PMN.116)
- lidocaine transdermal (Lidoderm, ZTlido) (PDF) (CP.PMN.08)
- Lifileucel (Amtagvi) (PDF) (CP.PHAR.598)
- Lifitegrast (Xiidra®) (PDF) (CP.PMN.73)
- Linezolid (Zyvox) (PDF) (CP.PMN.27)
- Lisocabtagene Maraleucel (Breyanzi) (PDF) (CP.PHAR.483)
- Lofexidine (Lucemyra) (PDF) (CP.PMN.152)
- Lomustine (Gleostine) (PDF) (CP.PHAR.507)
- Lonafarnib (Zokinvy) (PDF) (CP.PHAR.499)
- Loncastuximab Tesirine-lpyl (Zynlonta) (PDF) (CP.PHAR.539)
- Long-term Antibiotic Treatment for Tick-borne Diseases (PDF) (CP.PMN.279)
- Lorlatinib (Lorbrena) (PDF) (CP.PHAR.406)
- Loteprednol etabonate (Eysuvis) (PDF) (CP.PMN.260)
- Lotilaner (Xdemvy) (PDF) (CP.PMN.291)
- Lovotibeglogene Autotemcel (Lyfgenia) (PDF) (CP.PHAR.627)
- Lubiprostone (Amitiza) (PDF) (CP.PMN.142)
- Luliconazole Cream (Luzu) (PDF) (CP.PMN.166)
- Lumacaftor-ivacaftor (PDF) (CP.PHAR.213)
- Lumasiran (Oxlumo) (PDF) (CP.PHAR.473)
- Lumateperone (Caplyta) (PDF) (CP.PMN.232)
- Lurasidone (Latuda) (PDF) (CP.PMN.50)
- Lurbinectedin (Zepzelca) (PDF) (CP.PHAR.500)
- Luspatercept-aamt (Reblozyl) (PDF) (CP.PHAR.450)
- Lusutrombopag (Mulpleta) (PDF) (CP.PHAR.407)
- Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) (PDF) (CP.PHAR.582)
- Lutetium Lu 177 Dotatate (Lutathera) (PDF) (CP.PHAR.384)
- Macitentan (Opsumit) (PDF) (CP.PHAR.194)
- Mannitol (Bronchitol) (PDF) (CP.PHAR.518)
- Maralixibat (Livmarli) (PDF) (CP.PHAR.543)
- Margetuximab-cmkb (Margenza) (PDF) (CP.PHAR.522)
- Maribavir (Livtencity) (PDF) (CP.PMN.271)
- Mavacamten (Camzyos) (PDF) (CP.PMN.272)
- Mavorixafor (Xolremdi) (PDF) (CP.PHAR.679)
- Mecamylamine (Vecamyl) (PDF) (CP.PMN.136)
- Mecaserim (PDF) (CP.PHAR.150)
- Mechlorethamine Gel (Valchlor) (PDF) (CP.PHAR.381)
- Megestrol Acetate (Megace ES) (PDF) (CP.PMN.179)
- Melphalan flufenamide (Pepaxto) (PDF) (CP.PHAR.535)
- Melphalan (Hepzato) (PDF) (CP.PHAR.653)
- Memantine ER (Namenda XR), Memantine/Donepezil (Namzaric) (PDF) (CP.PCH.30)
- Mepolizumab (Nucala) (PDF) (CP.PHAR.200)
- Mercaptopurine (Purixan) (PDF) (CP.PHAR.447)
- Metformin ER (Fortamet, Glumetza) (PDF) (CP.PMN.72)
- Methotrexate (Otrexup, Rasuvo, Xatmep) (PDF) (CP.PHAR.134)
- Methoxsalen (Uvadex) (PDF) (HIM.PA.17)
- Methoxy polyethylene glycol-epoetin beta (Mircera) (PDF) (CP.PHAR.238)
- Methylnaltrexone Bromide (Relistor) (PDF) (CP.PMN.169)
- Metoclopramide (Gimoti) (PDF) (CP.PMN.252)
- Metreleptin (Myalept) (PDF) (CP.PHAR.425)
- Midazolam (Nayzilam) (PDF) (CP.PMN.211)
- Midostaurin (Rydapt) (PDF) (CP.PHAR.344)
- Migalastat (Galafold) (PDF) (CP.PHAR.394)
- Miglustat (Zavesca) (PDF) (CP.PHAR.164)
- Milnacipran (Savella) (PDF) (CP.PMN.125)
- Minocycline ER (Solodyn, Ximino, Minolira) and Microspheres (Arestin), Foam (Zilxi) (PDF) (CP.PMN.80)
- Mirvetuximab soravatansine-gynx (Elahere) (PDF) (CP.PHAR.617)
- Mitapivat (Pyrukynd) (PDF) (CP.PHAR.558)
- Mitomycin for Pyelocalyceal Solution (Jelmyto) (PDF) (CP.PHAR.495)
- Mitoxantrone (Novantrone) (PDF) (CP.PHAR.258)
- Mobocertinib (Exkivity) (PDF) (CP.PHAR.559)
- Modafinil (Provigil) (PDF) (CP.PMN.39)
- Mogamulizumab-kpkc (Poteligeo) (PDF) (CP.PHAR.139)
- Momelotinib (Ojjaara) (PDF) (CP.PHAR.654)
- Mometasone (Nasonex) (PDF) (HIM.PA.93)
- Mometasone Furoate (Sinuva) (PDF) (CP.PHAR.448)
- Mosunetuzumab-axgb (Lunsumio) (PDF) (CP.PHAR.618)
- Motixafortide (Aphexda) (PDF) (CP.PHAR.655)
- Moxetumomab pasudotox-tdfk (Lumoxiti) (PDF) (CP.PHAR.398)
- Nabumetone Double-Strength (Relafen DS) (PDF) (CP.PMN.287)
- Nadofaragene Firadenovec-vncg (Adstiladrin) (PDF) (CP.PHAR.461)
- nafarelin acetate (Synarel®) (PDF) (CP.PHAR.174)
- Naldemedine (Symproic) (PDF) (CP.PMN.112)
- Nalmefene (Opvee) (PDF) (CP.PHAR.638)
- Naloxegol (Movantik) (PDF) (HIM.PA.167)
- Naltrexone (Vivitrol®) (PDF) (CP.PHAR.96)
- Naproxen/Esomeprazole (Vimovo) (PDF) (CP.PMN.117)
- Naproxen oral suspension (Naprosyn) (PDF) (HIM.PA.130)
- Natalizumab (Tysabri) (PDF) (CP.PHAR.259)
- Naxitamab-gqgk (Danyelza) (PDF) (CP.PHAR.523)
- necitumumab (Portrazza®) (PDF) (CP.PHAR.320)
- Nedosiran (Rivfloza) (PDF) (CP.PHAR.619)
- Neomycin/Fluocinolone Cream (Neo-Synalar) (PDF) (CP.PMN.167)
- Neratinib (Nerlynx) (PDF) (CP.PHAR.365)
- Netupitant and Palonosetron (Akynzeo) (PDF) (CP.PMN.158)
- Nifurtimox (Lampit) (PDF) (CP.PMN.256)
- Nilotinib (Tasigna) (PDF) (CP.PHAR.76)
- Nintedanib (Ofev) (PDF) (CP.PHAR.285)
- Niraparib (Zejula) (PDF) (CP.PHAR.408)
- Niraparib and Abiraterone Acetate (Akeega) (PDF) (CP.PHAR.645)
- Nirmatrelvir and Ritonavir (Paxlovid) (PDF) (CP.PMN.288)
- Nirogacestat (Ogsiveo) (PDF) (CP.PHAR.671)
- Nirsevimab-alip (Beyfortus) (PDF) (CP.PHAR.614)
- Nitazoxanide (Alinia) (PDF) (HIM.PA.152)
- Nitisinone (Nityr, Orfadin) (PDF) (CP.PHAR.132)
- Nivolumab (PDF) (CP.PHAR.121)
- Nivolumab and Relatlimab-rmbw (Opdualag) (PDF) (CP.PHAR.588)
- Nogapendekin Alfa Inbakicept-pmln (Anktiva) (PDF) (CP.PHAR.684)
- Non-Calcium Phosphate Binders (PDF) (CP.PMN.04)
- Non-Formulary and Formulary Contraceptives (PDF) (HIM.PA.100)
- Non-Formulary Test Strips (PDF) (HIM.PA.34)
- Nusinersen (PDF) (CP.PHAR.327)
- Obeticholic Aacid (Ocaliva) (PDF) (CP.PHAR.287)
- obinutuzumab (Gazyva®) (PDF) (CP.PHAR.305)
- Ocrelizumab (Ocrevus) (PDF) (CP.PHAR.335)
- Octreotide Acetate (Sandostatin, Sandostatin LAR Depot) (PDF) (CP.PHAR.40)
- Odevixibat (Bylvay) (PDF) (CP.PHAR.528)
- Ofatumumab (Arzerra, Kesimpta) (PDF) (CP.PHAR.306)
- Off-Label Drug Use (PDF) (HIM.PA.154)
- Olanzapine Long-Acting Injection (Zyprexa Relprevv) (PDF) (CP.PHAR.292)
- Olanzapine/Samidorphan (Lybalvi) (PDF) (CP.PMN.265)
- Olaparib (Lynparza) (PDF) (CP.PHAR.360)
- Olipudase Alfa-rpcp (Xenpozyme) (PDF) (CP.PHAR.586)
- Olutasidenib (Rezlidhia) (PDF) (CP.PHAR.615)
- Omaveloxolone (Skyclarys) (PDF) (CP.PHAR.590)
- Omecetaxine (Synribo) (PDF) (CP.PHAR.108)
- Omadacycline (Nuzyra) (PDF) (CP.PMN.188)
- Omalizumab (Xolair) (PDF) (CP.PCH.49)
- OnabotulinumtoxinA (Botox) (PDF) (CP.PHAR.232)
- Onasemnogene abeparvovec (Zolgensma) (PDF) (CP.PHAR.421)
- Ondansetron (Zuplenz) (PDF) (CP.PMN.45)
- Opicapone (Ongentys) (PDF) (CP.PMN.245)
- Opioid Analgesics (PDF) (HIM.PA.139)
- Ophthalmic Corticosteroids (PDF) (HIM.PA.03)
- Ophthalmic Riboflavin (Photrexa, Photrexa Viscous) (PDF) (CP.PHAR.536)
- Osilodrostat (Isturisa) (PDF) (CP.PHAR.487)
- Osimertinib (Tagrisso) (PDF) (CP.PHAR.294)
- Ospemifene (Osphena) (PDF) (CP.PMN.168)
- Overactive Bladder Agents (PDF) (CP.PMN.198)
- Oxymetazoline (Rhofade, Upneeq) (PDF) (CP.PMN.86)
- Ozanimod (Zeposia) (PDF) (CP.PHAR.462)
- Ozenoxacin (Xepi) (PDF) (CP.PMN.119)
- Paclitaxel protein-bound (Abraxane) (PDF) (CP.PHAR.176)
- Pacritinib (Vonjo) (PDF) (CP.PHAR.583)
- Palbociclib (Ibrance) (PDF) (HIM.PA.173)
- Paliperidone Long-Acting Injections (Invega Hafyera, Invega Sustenna, Invega Trinza) (PDF) (CP.PHAR.291)
- Palivizumab (Synagis) (PDF) (CP.PHAR.16)
- Palovarotene (Sohonos) (PDF) (CP.PHAR.548)
- Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep) (PDF) (CP.PCH.44)
- panitumumab (Vectibix®) (PDF) (CP.PHAR.321)
- Panobinostat (Farydak) (PDF) (CP.PHAR.382)
- Parathyroid Hormone (Natpara) (PDF) (CP.PHAR.282)
- Paricalcitrol Injection (PDF) (CP.PHAR.270)
- pasireotide (Signifor LAR®) (PDF) (CP.PHAR.332)
- Patiromer (Veltassa) (PDF) (CP.PMN.205)
- Patisiran (Onpattro) (PDF) (CP.PHAR.395)
- Pazopanib (PDF) (CP.PHAR.81)
- Peanut Allergen Powder-dnfp (Palforzia) (PDF) (CP.PMN.220)
- pegaspargase (Oncaspar®) (PDF) (CP.PHAR.353)
- Pegcetacoplan (Empaveli) (PDF) (CP.PHAR.524)
- Pegfilgrastim (PDF) (CP.PHAR.296)
- Peginterferon beta-1a (Plegridy) (PDF) (CP.PHAR.271)
- Pegloticase (Krystexxa®) (PDF) (CP.PHAR.115)
- Pegunigalsidase Alfa-iwxj (Elfabrio) (PDF) (CP.PHAR.512)
- Pegvaliase-pqpz (Palynziq) (PDF) (CP.PHAR.140)
- Pegvisomant (Somavert) (PDF) (CP.PHAR.389)
- Pembrolizumab (Keytruda®) (PDF) (CP.PHAR.322)
- Pemetrexed (Alimta®) (PDF) (CP.PHAR.368)
- Pemigatinib (Pemazyre) (PDF) (CP.PHAR.496)
- Penicillamine (Cuprimine) (PDF) (CP.PCH.09)
- Perampanel (Fycompa) (PDF) (CP.PMN.156)
- Perfluorohexyloctane (Miebo) (PDF) (CP.PMN.290)
- Pertuzumab (Perjeta) (PDF) (CP.PHAR.227)
- Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (Phesgo) (PDF) (CP.PHAR.501)
- Pexidartinib (Turalio) (PDF) (CP.PHAR.436)
- Phendimetrazine (PDF) (CP.PCH.47)
- Phentermine (Adipex-P, Lomaira) (PDF) (CP.PCH.13)
- Pilocarpine (Vuity) (PDF) (CP.PMN.270)
- Pimavanserin (Nuplazid) (PDF) (CP.PMN.140)
- Pirfenidone (Esbriet) (PDF) (CP.PHAR.286)
- Pirtobrutinib (Jaypirca) (PDF) (CP.PHAR.620)
- Pitolisant (Wakix) (PDF) (CP.PMN.221)
- Plasminogen, human-tvmh (Ryplazim) (PDF) (CP.PHAR.513)
- Plecanatide (Trulance) (PDF) (CP.PMN.87)
- Plerixafor (PDF) (CP.PHAR.323)
- Polatuzumab Vedotin-piiq (Polivy) (PDF) (CP.PHAR.433)
- Pomalidomide (Pomalyst) (PDF) (CP.PHAR.116)
- Ponatinib (Iclusig) (PDF) (CP.PHAR.112)
- Ponesimod (Ponvory) (PDF) (CP.PHAR.537)
- Potassium (Klor-Con) (PDF) (HIM.PA.143)
- Pozelimab-bbfg (Veopoz) (PDF) (CP.PHAR.626)
- pralatrexate (Folotyn®) (PDF) (CP.PHAR.313)
- Pramlintide (Symlin) (PDF) (CP.PMN.129)
- Prasterone (Intrarosa) (PDF) (CP.PMN.99)
- Pregabalin (Lyrica, Lyrica CR) (PDF) (CP.PMN.33)
- Pretomanid (PDF) (CP.PMN.222)
- Progesterone (Crinone, Endometrin, Milprosa) (PDF) (CP.PMN.243)
- protein c concentrate, human (Ceprotin®) (PDF) (CP.PHAR.330)
- Propranolol HCl Oral Solution (Hemangeol) (PDF) (CP.PCH.51)
- Prucalopride (Motegrity) (PDF) (HIM.PA.159)
- pyrimethamine (Daraprim®) (PDF) (CP.PMN.44)
- Quantity Limit Override and Dose Optimization (PDF) (CP.PMN.59)
- Quetiapine ER (Seroquel XR) (PDF) (CP.PMN.64)
- Quinine Sulfate (Qualaquin) (PDF) (CP.PNM.262)
- Quizartinib (Vanflyta) (PDF) (CP.PHAR.646)
- Tivozanib (Fotivda) (PDF) (CP.PHAR.538)
- Ranibizumab (Byooviz, Cimerli, Lucentis, Susvimo) (PDF) (CP.PHAR.186)
- rasagiline (Azilect®) (PDF) (HIM.PA.89)
- Ravulizumab-cwvz (Ultomiris) (PDF) (CP.PHAR.415)
- Regorafenib (Stivarga) (PDF) (CP.PHAR.107)
- Relugolix (Orgovyx) (PDF) (CP.PHAR.529)
- Repository Corticotropin Injection (H.P. Acthar Gel, Purified Cortrophin Gel) (PDF) (HIM.PA.168)
- Repotrectinib (Augtyro) (PDF) (CP.PHAR.667)
- Reslizumab (Cinqair) (PDF) (CP.PHAR.223)
- Resmetirom (Rezdiffra) (PDF) (CP.PHAR.647)
- Respiratory syncytial virus vaccine (Abrysvo) (PDF) (CP.PHAR.658)
- Retifanlimab-dlwr (Zynyz) (PDF) (CP.PHAR.629)
- Revlimid (PDF) (CP.PHAR.71)
- Ribavirin (Rebetol, Ribasphere) (PDF) (CP.PHAR.141)
- Ribociclib (Kisqali), Ribociclib/Letrozole (Kisqali Femara) (PDF) (CP.PHAR.334)
- Rifabutin (Mycobutin) (PDF) (CP.PMN.223)
- Rifamycin (Aemcolo) (PDF) (CP.PMN.196)
- Rilonacept (Arcalyst) (PDF) (CP.PHAR.266)
- RimabotulinumtoxinB (Myobloc) (PDF) (CP.PHAR.233)
- Rimegepant (Nurtec ODT) (PDF) (CP.PHAR.490)
- Riociguat (Adempas®) (PDF) (CP.PHAR.195)
- Ripretinib (Qinlock) (PDF) (CP.PHAR.502)
- Risdiplam (Evrysdi) (PDF) (CP.PHAR.477)
- Risedronate (Actonel, Atelvia) (PDF) (CP.PMN.100)
- Risperidone LA Inj (PDF) (CP.PHAR.293)
- rifaximin (PDF) (CP.PMN.47)
- Rituximab (Rituxan, Riabni, Ruxience, Truxima, Rituxan Hycela) (PDF) (CP.PHAR.260)
- Roflumilast (Daliresp, Zoryve) (PDF) (CP.PMN.46)
- Rolapitant (Varubi) (PDF) (CP.PMN.102)
- Romidepsin (Istodax) (PDF) (CP.PHAR.314)
- Romiplostim (Nplate®) (PDF) (CP.PHAR.179)
- Romosozumab-aqqg (Evenity) (PDF) (CP.PHAR.428)
- Ropeginterferon Alfa-2b-njft (BESREMi) (PDF) (CP.PHAR.570)
- Rozanolixizumab-noli (Rystiggo) (PDF) (CP.PHAR.648)
- Rucaparib (Rubraca®) (PDF) (CP.PHAR.350)
- Rufinamide (Banzel) (PDF) (CP.PMN.157)
- Rukobia (fostemsavir) (PDF) (CP.PHAR.516)
- Ruxolitinib (Jakafi, Opzelura) (PDF) (CP.PHAR.98)
- Sacituzumab Govitecan-hziy (Trodelvy) (PDF) (CP.PHAR.475)
- Sacubitril/Valsartan (Entresto) (PDF) (CP.PMN.67)
- Sacubitril/Valsartan (Entresto) (PDF) (CP.PCH.52)
- Safinamide (Xadago) (PDF) (CP.PMN.113)
- Sapropterin (Kuvan) (PDF) (CP.PHAR.43)
- Sarecycline (Seysara) (PDF) (CP.PMN.189)
- Sargramostim (PDF) (CP.PHAR.295)
- Satralizumab (PDF) (CP.PHAR.463)
- Sebelipase Alfa (Kanuma) (PDF) (CP.PHAR.159)
- Secnidazole (Solosec) (PDF) (CP.PMN.103)
- Selexipag (Uptravi®) (PDF) (CP.PHAR.196)
- Selinexor (Xpovio) (PDF) (CP.PHAR.431)
- Selpercatinib (Retevmo) (PDF) (CP.PHAR.478)
- Selumetinib (PDF) (CP.PHAR.464)
- Semaglutide (Wegovy) (PDF) (CP.PMN.295)
- Sensipar (PDF) (CP.PHAR.61)
- Setmelanotide (Imcivree) (PDF) (CP.PHAR.491)
- Short Ragweed Pollen Allergen Extract (Ragwitek) (PDF) (CP.PMN.83)
- Sildenafil (Revatio®) (PDF) (CP.PHAR.197)
- Sildenafil (Viagra) (PDF) (CP.PCH.07)
- Siltuximab (Sylvant®) (PDF) (CP.PHAR.329)
- Siponimod (Mayzent) (PDF) (CP.PHAR.427)
- Sirolimus Protein-Bound Particles (Fyarro) (PDF) (CP.PHAR.574)
- Sodium-Glucose Co-Transporter 2 Inhibitors (PDF) (HIM.PA.91)
- Sodium Oxybate (Xyrem) and Calcium, Magnesium, Potassium, Sodium Oxybate (Xywav) (PDF) (CP.PMN.42)
- Sodium Phenylbutyrate (Buphenyl) (PDF) (CP.PHAR.208)
- Sodium Phenylbutyrate/Taurursodiol (Relyvrio) (PDF) (CP.PHAR.584)
- Sodium thiosulfate (Pedmark) (PDF) (CP.PHAR.610)
- Sodium Zirconium Cyclosilicate (Lokelma) (PDF) (CP.PMN.163)
- Sofosbuvir (Sovaldi) (PDF) (HIM.PA.SP2)
- Sofosbuvir/Vepatasvir/Voxilaprevir (Vosevi) (PDF) (HIM.PA.SP63)
- Sofosbuvir-Velpatasvir (Epclusa) (PDF) (HIM.PA.SP1)
- Solriamfetol (Sunosi) (PDF) (CP.PMN.209)
- Sonidegib (Odomzo) (PDF) (CP.PHAR.272)
- Sorafenib (Nexavar) (PDF) (CP.PHAR.69)
- Sotatercept (Winrevair) (PDF) (CP.PHAR.657)
- Sotorasib (Lumakras) (PDF) (CP.PHAR.549)
- Sparsentan (Filspari) (PDF) (CP.PHAR.631)
- Spesolimab-sbzo (Spevigo) (PDF) (CP.PHAR.606)
- Spinosad (Natroba) (PDF) (HIM.PA.134)
- Step Therapy Criteria (PDF) (HIM.PA.109)
- Stiripentol (Diacomit) (PDF) (CP.PMN.184)
- Sunitinib (Sutent) (PDF) (CP.PHAR.73)
- Sutimlimab-jome (Enjaymo) (PDF) (CP.PHAR.503)
- Suvorexant (Belsomra) (PDF) (CP.PMN.109)
- Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract (Oralair) (PDF) (CP.PMN.85)
- Sylatron (peginterferon alfa-2b) (PDF) (CP.PHAR.89)
- Tadalafil (Adcirca®) (PDF) (CP.PHAR.198)
- Tadafil BHP - ED (Cialis) (PDF) (CP.PMN.132)
- Tafamidis (Vyndaqel, Vyndamax) (PDF) (CP.PHAR.432)
- Tafasitamab-cxix (Monjuvi) (PDF) (CP.PHAR.508)
- Talazoparib (Talzenna) (PDF) (CP.PHAR.409)
- Taliglucerase Alfa (Elelyso) (PDF) (CP.PHAR.157)
- Taliglucerase Alfa (Elelyso) (PDF) (HIM.PA.162)
- Talimogene laherepvec (Imlygic) (PDF) (CP.PHAR.542)
- Talquetamab-tgvs (Talvey) (PDF) (CP.PHAR.649)
- Tapinarof (Vtama) (PDF) (CP.PMN.283)
- Tarlatamab-dlle (Imdelltra) (PDF) (CP.PHAR.685)
- Tasimelteon (Hetlioz) (PDF) (CP.PMN.104)
- Tavaborole (Kerydin®) (PDF) (CP.PMN.105)
- Tazemetostat (PDF) (CP.PHAR.452)
- Tazarotene (Arazlo, Fabior, Tazorac) (PDF) (CP.PMN.244)
- Tebentafusp-tebn (Kimmtrak) (PDF) (CP.PHAR.575)
- Teclistamab-cqyv (Tecvayli) (PDF) (CP.PHAR.611)
- Tedizolid (Sivextro) (PDF) (CP.PMN.62)
- Teduglutide (Gattex) (PDF) (CP.PHAR.114)
- Tegaserod (Zelnorm) (PDF) (HIM.PA.160)
- Telotristat ethyl (Xermelo) (PDF) (CP.PHAR.337)
- Temozolomide (Temodar) (PDF) (CP.PHAR.77)
- Temsirolimus (Torisel) (PDF) (CP.PHAR.324)
- Tetrabenazine (Xenazine) (PDF) (CP.PHAR.92)
- Tenapanor (Ibsrela, Xphozah) (PDF) (HIM.PA.174)
- Tenofovir Alafenamide Fumarate (Vemlidy) (PDF) (CP.PMN.268)
- Teplizumab-mzwv (Tzield) (PDF) (CP.PHAR.492)
- Tepotinib (Tepmetko) (PDF) (CP.PHAR.530)
- Teprotumumab (Tepezza) (PDF) (CP.PHAR.465)
- Teriflunomide (Aubagio) (PDF) (CP.PCH.40)
- Teriparatide (Forteo®) (PDF) (CP.PHAR.188)
- Tesamorelin (PDF) (CP.PHAR.109)
- Testosterone (Testopel, Jatenzo) (PDF) (CP.PHAR.354)
- Tezacaftor/Ivacaftor; Ivacaftor (Symdeko) (PDF) (CP.PHAR.377)
- Tezepelumab-ekko (Tezspire) (PDF) (CP.PHAR.576)
- Thalidomide (Thalomid) (PDF) (CP.PHAR.78)
- Thioguanine (Tabloid) (PDF) (CP.PHAR.437)
- Thyrotropin alfa (PDF) (CP.PHAR.95)
- Timothy Grass Pollen Allergen Extract (Grastek) (PDF) (CP.PMN.84)
- Tiopronin Delayed-Release (Thiola EC) (PDF) (CP.PCH.50)
- Tisagenlecleucel (PDF) (CP.PHAR.361)
- Tislelizumab-jsgr (Tevimbra) (PDF) (CP.PHAR.687)
- Tisotumab Vedotin-tftv (Tivdak) (PDF) (CP.PHAR.561)
- Tobramycin (Bethkis®, Kitabis Pak®, TOBI®, TOBI Podhaler®) (PDF) (CP.PHAR.211)
- Tofersen (Qalsody) (PDF) (CP.PHAR.591)
- Tolvaptan (Jynarque) (PDF) (CP.PHAR.27)
- Topical Acne Treatment (PDF) (HIM.PA.71)
- Topical Immunomodulators (PDF) (CP.PMN.107)
- topical testosterone (PDF) (HIM.PA.87)
- Topiramate Extended-Release (Qudexy XR, Trokendi XR) (PDF) (CP.PMN.281)
- Topotecan (Hycamtin) (PDF) (CP.PHAR.64)
- Toripalimab-tpzi (Loqtorzi) (PDF) (CP.PHAR.668)
- Tovorafenib (Ojemda) (PDF) (CP.PHAR.686)
- Trabectedin (Yondelis®) (PDF) (CP.PHAR.204)
- Tralokinumab-ldrm (Adbry) (PDF) (CP.PHAR.577)
- Trametinib (Mekinist) (PDF) (CP.PHAR.240)
- Trastuzumab Biosimilars Trastuzumab-Hyaluronidase (PDF) (CP.PHAR.228)
- Travoprost Implant (iDose TR) (PDF) (CP.PHAR.672)
- Tremelimumab-actl (Imjudo) (PDF) (CP.PHAR.612)
- Treprostinil (Orenitram®, Remodulin®, Tyvaso®) (PDF) (CP.PHAR.199)
- Triamcinolone ER Injection (Zilretta) (PDF) (CP.PHAR.371)
- Triclabendazole (Egaten) (PDF) (CP.PMN.207)
- Trientine (Cuvrior, Syprine) (PDF) (CP.PHAR.438)
- Trifarotene (Aklief) (PDF) (CP.PMN.225)
- Trifluridine/Tipiracil (Lonsurf) (PDF) (CP.PHAR.383)
- Triheptanoin (Dojolvi) (PDF) (CP.PHAR.509)
- triptorelin pamoate (Trelstar®, Triptodur®) (PDF) (CP.PHAR.175)
- Trofinetide (Daybue) (PDF) (CP.PHAR.600)
- Tucatinib (Tukysa) (PDF) (CP.PHAR.497)
- Ublituximab-xiiy (Briumvi) (PDF) (CP.PHAR.621)
- Ulcer Therapy Combinations (PDF) (CP.PMN.277)
- Umbralisib (Ukoniq) (PDF) (CP.PHAR.531)
- Uridine acetate (Vistogard) (PDF) (HIM.PA.SP55)
- Vadadustat (Vafseo) (PDF) (CP.PHAR.677)
- Valbenazine (Ingrezza) (PDF) (CP.PCH.48)
- valganciclovir (Valcyte) (PDF) (CP.PCH.06)
- Valoctocogene Roxaparvovec-rvox (Roctavian) (PDF) (CP.PHAR.466)
- Valrubicin (Valstar) (PDF) (CP.PHAR.439)
- Vamorolone (Agamree) (PDF) (CP.PHAR.659)
- Vandetanib (Caprelsa®) (PDF) (CP.PHAR.80)
- Varenicline (Tyrvaya) (PDF) (CP.PMN.273)
- Velaglucerase Alfa (VPRIV) (PDF) (CP.PHAR.163)
- Velaglucerase Alfa (VPRIV) (PDF) (HIM.PA.163)
- Velmanase Alfa-tycv (Lamzede) (PDF) (CP.PHAR.601)
- Vemurafenib (Zelboraf®) (PDF) (CP.PHAR.91)
- Venetoclax (Venclexta) (PDF) (CP.PHAR.129)
- Verteporfin (Visudyne) (PDF) (CP.PHAR.187)
- Vestronidase alfa-vjbk (Mepsevii) (PDF) (CP.PHAR.374)
- Vigabatrin (PDF) (CP.PHAR.169)
- Viloxazine (Qelbree) (PDF) (CP.PMN.264)
- Viltolarsen (Viltepso) (PDF) (CP.PHAR.484)
- Vincristine Sulfate Liposome Injection (Marqibo) (PDF) (CP.PHAR.315)
- Vismodegib (Erivedge) (PDF) (CP.PHAR.273)
- Voclosporin (Lupkynis) (PDF) (CP.PHAR.504)
- Vorapaxar (Zontivity) (PDF) (HIM.PA.146)
- Voretigene neparvovec-rzyl (Luxturna) (PDF) (CP.PHAR.372)
- Vorinostat (Zolinza) (PDF) (CP.PHAR.83)
- Vortioxetine (Trintellix®) (PDF) (CP.PMN.65)
- Vosoritide (Voxzogo) (PDF) (CP.PHAR.525)
- Voxelotor (Oxbryta) (PDF) (CP.PHAR.451)
- Vutrisiran (Amvuttra) (PDF) (CP.PHAR.550)
- Xiaflex™ (PDF) (CP.PHAR.82)
- Zanubrutinib (Brukinsa) (PDF) (CP.PHAR.467)
- Zavegepant (Zavzpret) (PDF) (CP.PHAR.630)
- Zilucoplan (Zilbrysq) (PDF) (CP.PHAR.616)
- Ziv-aflibercept (Zaltrap) (PDF) (CP.PHAR.325)
- Zometa (PDF) (CP.PHAR.59)
- Zuranolone (Zurzuvae) (PDF) (CP.PHAR.650)
Medicaid Clinical Policies Listing
- Administrative Days (PDF) (WA.CP.MP.519)
- Allergy Testing and Therapy (PDF) (CP.MP.100)
- Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-Thalassemia (PDF) (CP.MP.108)
- Applied Behavior Analysis (PDF) (CP.BH.104)
- Applied Behavioral Analysis Documentation Requirements (PDF) (CP.BH.105)
- Appropriate Imaging for Breast Cancer Screening (PDF) (WA.CP.MP.531)
- Attention Deficit Hyperactivity Disorder Assessment and Treatment (PDF) (CP.BH.124)
- Bariatric Surgery (PDF) (WA.CP.MP.37)
- Behavioral Health Treatment Documentation Requirements (PDF) (CP.BH.500)
- Behavioral Health Wraparound Support (PDF) (WA.CP.BH.521)
- Bone-Anchored Hearing Aid (PDF) (CP.MP.93)
- Bone Morphogenic Proteins for Use in Spinal Fusion (PDF) (WA.CP.MP.530)
- Burn Surgery (PDF) (CP.MP.186)
- Cardiac Biomarker Testing (PDF) (CP.MP.156)
- Cardiac Stents (PDF) (WA.CP.MP.513)
- Carotid Artery Stenting (PDF) (WA.CP.MP.516)
- Catheter Ablation for Supraventricular Tachyarrhythmia (PDF) (WA.CP.MP.525)
- Clinical Trials (PDF) (CP.MP.94)
- Cochlear Implant Replacements (PDF) (CP.MP.14)
- Cochlear Implants (PDF) (WA.CP.MP.502)
- Community Behavioral Health Support: Supportive Supervision (PDF) (WA.CP.BH.529)
- Continuous Glucose Monitoring (PDF) (WA.CP.MP.501)
- Cosmetic and Reconstructive Procedures (PDF) (CP.MP.31)
- Diaphragmatic/Phrenic Nerve Stimulation (PDF) (CP.MP.203)
- Digital EEG Spike Analysis (PDF) (CP.MP.105)
- Disc Decompression Procedures (PDF) (CP.MP.114)
- Discography (PDF) (CP.MP.115)
- Donor Lymphocyte Infusion (PDF) (CP.MP.101)
- Drugs of Abuse: Definitive Testing (PDF) (WA.CP.MP.50)
- Durable Medical Equipment and Orthotics and Prosthetics Guidelines (DME) (PDF) (CP.MP.107)
- Electroencephalography in the Evaluation of Headache (PDF) (CP.MP.155)
- Elective Delivery Prior to 39 Weeks (PDF) (WA.CP.MP.504)
- Endometrial Ablation (PDF) (CP.MP.106)
- Evoked Potential Testing (PDF) (CP.MP.134)
- Experimental Technologies (PDF) (WA.CP.MP.36)
- Extracorporeal Membrane Oxygenation Therapy (PDF) (WA.CP.MP.514)
- Facility-based Sleep Studies for Obstructive Sleep Apnea (PDF) (CP.MP.248)
- Fecal Incontinence Treatments (PDF) (CP.MP.137)
- Fecal Microbiota Transplantation (PDF) (WA.CP.MP.515)
- Fertility Preservation (PDF) (WA.CP.MP.130)
- Fetal Surgery in Utero for Prenatally Diagnosed Malformations (PDF) (CP.MP.129)
- Gastric Electrical Stimulation (PDF) (CP.MP.40)
- Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing (PDF) (CP.MP.209)
- Helicobacter Pylori Serology Testing (PDF) (CP.MP.153)
- Heart-Lung Transplant (PDF) (CP.MP.132)
- Holter Monitors (PDF) (CP.MP.113)
- Home Births (PDF) (CP.MP.136)
- Home Prothrombin Time Monitoring (PDF) (WA.CP.MP.207)
- Home Ventilators (PDF) (CP.MP.184)
- Homocysteine testing (PDF) (CP.MP.121)
- Hospice Services (PDF) (WA.CP.MP.54)
- Hyperbaric Oxygen Therapy (PDF) (WA.CP.MP.27)
- Hyperhidrosis Treatments (PDF) (CP.MP.62)
- Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea (PDF) (CP.MP.180)
- Implantable Intrathecal or Epidural Pain Pump (PDF) (CP.MP.173)
- Implantable Loop Recorder (PDF) (CP.MP.243)
- Intensity-Modulated Radiotherapy (IMRT) (PDF) (WA.CP.MP.69)
- Intensive Behavioral Supportive Supervision (PDF) (WA.CP.BH.528)
- Intestinal and Multivisceral Transplant (PDF) (CP.MP.58)
- Intradiscal Steroid Injections for Pain Management (PDF) (CP.MP.167)
- IV Moderate Sedation, IV Deep Sedation and General Anesthesia for Dental Procedures (PDF) (CP.MP.61)
- Lantidra (donislecel): Allogeneic Pancreatic Islet Cellular Therapy (PDF) (CP.MP.250)
- Laser Therapy for Skin Conditions (PDF) (CP.MP.123)
- Liposuction of Lipedema (PDF) (CP.MP.244)
- Lung Transplantation (PDF) (CP.MP.57)
- Lysis of Epidural Lesions (PDF) (CP.MP.116)
- Mandibular Advancement Devices (PDF) (WA.CP.MP.500)
- Microprocessor Controlled Prosthetics (PDF) (WA.CP.MP.505)
- Migraine and Tension-Type Headaches (PDF) (WA.CP.MP.532)
- Multiple Sleep Latency Testing (PDF) (CP.MP.24)
- Negative Pressure Wound Therapy for Home Use (PDF) (WA.CP.MP.518)
- Neonatal Abstinence Syndrome Guidelines (PDF) (CP.MP.86)
- Neonatal Sepsis Management Guidelines (PDF) (CP.MP.85)
- Nerve Blocks and Neurolysis for Pain Management (PDF) (CP.MP.170)
- NICU Apnea Bradycardia Guidelines (PDF) (CP.MP.82)
- NICU Discharge Guidelines (PDF) (CP.MP.81)
- Nonmyeloablative Allogeneic Stem Cell Transplants (PDF)(CP.MP.141)
- Nonpharmacological Treatments for Depression (PDF) (WA.CP.BH.522)
- Omisirge (omidubicel): Nicotinamide-Modified Allogeneic Hematopoietic Progenitor Cell Therapy (PDF) (CP.MP.249)
- Oral Enteral Nutrition (PDF) (WA.CP.MP.507)
- Orthognathic Surgery (PDF) (CP.MP.202)
- Osteogenic Stimulation (PDF) (WA.CP.MP.194)
- Pancreas Transplantation (PDF) (CP.MP.102)
- Panniculectomy (PDF) (CP.MP.109)
- Pediatric Heart Transplant (PDF) (CP.MP.138)
- Pediatric Liver Transplant (PDF) (CP.MP.120)
- Pediatric Kidney Transplant (PDF) (CP.MP.246)
- Pediatric Oral Function Therapy (PDF) (CP.MP.188)
- Peripheral and Percutaneous Nerve Stimulation (PDF) (WA.CP.MP.117)
- Photherapy for Neonatal Hyperbilirubinemia (PDF) (CP.MP.150)
- Physical, Occupational, and Speech Therapy Services (PDF) (CP.MP.49)
- Polymerase Chain Reaction Respiratory Viral Panel Testing (PDF) (CP.MP.181)
- Private Duty Nursing Services (PDF) (WA.CP.MP.503)
- Proton and Neutron Beam Therapies (PDF) (WA.CP.MP.70)
- Pulmonary Function Testing (PDF) (CP.MP.242)
- Reduction Mammoplasty and Gynecomastia Surgery (PDF) (CP.MP.51)
- Repair of Nasal Valve Compromise (PDF) (CP.MP.210)
- Short Inpatient Hospital Stay (PDF) (CP.MP.182)
- Skin and Soft Tissue Substitutes for Chronic Wounds (PDF) (WA.CP.MP.185)
- Stem Cell Therapy for Musculoskeletal Conditions (PDF) (WA.CP.MP.526)
- Stereotactic Body Radiation Therapy (PDF) (WA.CP.MP.22)
- Tandem Transplant (PDF) (CP.MP.162)
- Testosterone Testing (PDF) (WA.CP.MP.517)
- Therapeutic Utilization of Inhaled Nitric Oxide (PDF) (CP.MP.87)
- Thyroid Hormones and Insulin Testing in Pediatrics (PDF) (CP.MP.154)
- Tinnitus Treatment (PDF) (WA.CP.MP.510)
- Total Artificial Heart (PDF) (CP.MP.127)
- Total Parenteral Nutrition and Intradialytic Parenteral Nutrition (PDF) (CP.MP.163)
- Transcatheter Closure of Patent Foramen Ovale (PDF) (CP.MP.151)
- Transcranial Magnetic Stimulation for Treatment Resistant Major Depression (PDF) (WA.CP.BH.200)
- Transplant Service Documentation Requirements (PDF) (CP.MP.247)
- Trigger Point Injections for Pain Management (PDF) (CP.MP.169)
- Tympanostomy Tubes in Children (PDF) (WA.CP.MP.520)
- Ultrasound in Pregnancy (PDF) (CP.MP.38)
- Upper GI Endoscopy for GERD (PDF) (WA.CP.MP.509)
- Upright MRI (PDF) (WA.CP.MP.534)
- Urinary Incontinence Devices and Treatments (PDF) (CP.MP.142)
- Urodynamic Testing (PDF) (CP.MP.98)
- Vagus Nerve Stimulation (PDF) (WA.CP.MP.12)
- Varicose Vein Treatment (PDF) (WA.CP.MP.522)
- Ventricular Assist Devices (PDF) (WA.CP.MP.46)
- Vitamin D Testing (PDF) (WA.CP.MP.527)
- Concert Genetic Testing: Aortopathies & Connective Tissue Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Cardiac Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Dermatologic Conditions (PDF) (V2.2024)
- Concert Genetic Testing: Epilepsy, Neurodegenerative, and Neuromuscular Conditions (PDF) (V2.2024)
- Concert Genetic Testing: Exome and Genome Sequencing for Diagnosis of Genetic Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Eye Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Gastroenterologic Disorders (non-cancerous) (PDF) (V2.2024)
- Concert Genetic Testing: General Approach to Genetic and Molecular Testing (PDF) (V2.2024)
- Concert Genetic Testing: Hearing Loss (PDF) (V2.2024)
- Concert Genetic Testing: Hematologic Conditions (non-cancerous) (PDF) (V2.2024)
- Concert Genetic Testing: Hereditary Cancer Susceptibility (PDF) (V2.2024)
- Concert Genetic Testing: Immune, Autoimmune, and Rheumatoid Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Kidney Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Lung Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Metabolic, Endocrine, and Mitochondrial Disorders (PDF) (V2.2024)
- Concert Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay (PDF) (WA.CP.MP.230)
- Concert Genetic Testing: Non-Invasive Prenatal Screening (NIPS) (PDF) (WA.CP.MP.231)
- Concert Genetic Testing: Pharmacogenetics (PDF) (WA.CP.MP.232)
- Concert Genetic Testing: Preimplantation Genetic Testing (PDF) (V2.2024)
- Concert Genetic Testing: Prenatal and Preconception Carrier Screening (PDF) (V2.2024)
- Concert Genetic Testing: Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss (PDF) (V2.2024)
- Concert Genetic Testing: Skeletal Dysplasia and Rare Bone Disorders (PDF) (V2.2024)
- Concert Genetics Oncology: Algorithmic Testing (PDF) (V2.2024)
- Concert Genetics Oncology: Cancer Screening (PDF) (V2.2024)
- Concert Genetics Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy) (PDF) (V2.2024)
- Concert Genetics Oncology: Cytogenetic Testing (PDF) (V2.2024)
- Concert Genetics Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies (PDF) (V2.2024)
Medicaid Pharmacy Policies Listing
- 72-Hour Emergency Supply of Medication (PDF) (CC.PHAR.01)
- Abametapir (Xeglyze) (PDF) (CP.PMN.253)
- Abemaciclib (PDF) (CP.PHAR.355)
- AbobotulinumtoxinA (Dysport) (PDF) (CP.PHAR.230)
- Abrocitinib (Cibinqo) (PDF) (CP.PHAR.578)
- ACEI and ARB Duplicate Therapy (PDF) (CP.PMN.61)
- Acitretin (Soriatane) (PDF) (CP.PMN.40)
- Acyclovir Buccal Tablet (Sitavig), Ophthalmic Ointment (Avaclyr) (PDF) (CP.PMN.210)
- Acute Migraine Treatment Calcitonin Gene Related Peptide (CGRP) Receptor Antagonist (PDF) (WA.PHAR.106)
- Adagrasib (Krazati) (PDF) (CP.PHAR.605)
- Adefovir (Hepsera) (PDF) (CP.PHAR.142)
- ADHD Anti Narcolepsy Agents Armodafinil modafinil Sunosi Wakix (PDF) (WA.PHAR.124)
- ADHD Anti-Narcolepsy Non-Stimulants Viloxazine (Qelbree) (PDF) (WA.PHAR.131)
- Ado-Trastuzumab (Kadcyla) (PDF) (CP.PHAR.229)
- Adzynma (ADAMTS13, Recombinant-krhn) (PDF) (CP.PHAR.635)
- Aflibercept (Eylea, Eylea HD), Aflibercept-yszy (Opuviz), Aflibercept-jbvf (Yesafili), Aflibercept-mrbb (Ahzantive) (PDF) (CP.PHAR.184)
- Age Limit for Topical Tretinoin (PDF) (CP.PMN.191)
- Agents for Sickle Cell Anemia L-glutamine (ENDARI) (PDF) (WA.PHAR.59)
- Alemtuzumab (Lemtrada) (PDF) (CP.PHAR.243)
- Allergenic Extracts (Oral) (PDF) (WA.PHAR.27)
- Allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen-dsat (StrataGraft) (PDF) (CP.PHAR.562)
- Alpelisib (Piqray, Vijoice) (PDF) (CP.PHAR.430)
- Amantadine ER (PDF) (CP.PMN.89)
- Amikacin (Arikayce) (PDF) (CP.PHAR.401)
- Amisulpride (Barhemsys) (PDF) (CP.PMN.236)
- Amivantamab-vmjw (Rybrevant) (PDF) (CP.PHAR.544)
- Amlodipine/Atorvastatin (Caduet) (PDF) (CP.PMN.176)
- Analgesics Opioid Agonists (PDF) (WA.PHAR.23)
- Androgenic Agents-Testosterone Replacement Therapy (TRT) (PDF) (WA.PHAR.28)
- Anifrolumab-fnia (Saphnelo) (PDF) (CP.PHAR.551)
- Antiasthmatic Monoclonal Antibodies - Anti IgE Antibodies (PDF) (WA.PHAR.29)
- Antiasthmatic Monoclonal Antibodies IL-5 Antagonists (PDF) (WA.PHAR.30)
- Antibiotics Anti-Infective Agents- Oral rifaximin (XIFAXAN) (PDF) (WA.PHAR.66)
- Antibiotics-Inhaled-aminoglycosides (PDF) (WA.PHAR.79)
- Antibiotics Inhaled aztreonam (CAYSTON) (PDF) (WA.PHAR.31)
- Anticonvulsants-Rescue Agents (PDF) (WA.PHAR.32)
- Antidepressants- Serotonin Modulators (PDF) (WA.PHAR.123)
- Antidiabetics-Amylin Analogs (PDF) (WA.PHAR.33)
- Antidiabetics- GLP-1 Agonists (PDF) (WA.PHAR.122)
- Antidiabetics-Inhaled Insulin (Afrezza) (PDF) (WA.PHAR.34)
- Antihyperlipidemics-Apolipoprotein B Synthesis Inhibitors lomitapide mesylate (PDF) (WA.PHAR.38)
- Antihyperlipidemics - icosapent ethyl (Vascepa) (PDF) (WA.PHAR.134)
- Antihyperlipidemics-PCSK9 Inhibitors (PDF) (WA.PHAR.39)
- Antineoplastics and Adjunctive Therapies - Imidazotetrazines– Oral (PDF) (WA.PHAR.117)
- Antimemetic-Antivertigo Agents (Dronabinol) (PDF) (WA.PHAR.35)
- Antineoplastics and Adjunctive Therapies Tyrosine Kinase Inhibitors (PDF) (WA.PHAR.103)
- Antiparasitics Antiprotozoal Agents- nitazoxanide (Alinia) (PDF) (WA.PHAR.67)
- Antipsychotics 2nd Generation Vraylar (PDF) (WA.PHAR.105)
- Antithrombin III (ATryn, Thrombate III) (PDF) (CP.PHAR.564)
- Antithymocyte Globulin (Atgam, Thymoglobulin) (PDF) (CP.PHAR.506)
- Antivirals-HIV Combinations (PDF) (WA.PHAR.97)
- Antivirals HIV-emtricitabinetenofovir alafenamide (Descovy) (PDF) (WA.PHAR.98)
- Antivirals HIV- Rilpivirine (Edurant) (PDF) (WA.PHAR.120)
- Apalutamide (Erleada) (PDF) (CP.PHAR.376)
- Apomorphine (Apokyn, Kynmobi) (PDF) (CP.PHAR.488)
- Aprepitant (PDF) (CP.PMN.19)
- Aprocitentan (Tryvio) (PDF) (CP.PHAR.676)
- aripiprazole long-acting injections (PDF) (CP.PHAR.290)
- Asenapine (Saphris, Secuado) (PDF) (CP.PMN.15)
- Aspirin-dipyridamole (PDF) (CP.PMN.20)
- Atezolizumab (Tecentriq) (PDF) (CP.PHAR.235)
- Atopic Dermatitis Agents Dupilumab (Dupixent) (PDF) (WA.PHAR.41)
- Atopic Dermatitis Agents-Topical Immunosuppressives (PDF) (WA.PHAR.42)
- Atopic Dermatitis Agents Crisaborole (Eucrisa) (PDF) (WA.PHAR.43)
- Avacincaptad pegol (Izervay) (PDF) (CP.PHAR.641)
- Avelumab (Bavencio) (PDF) (CP.PHAR.333)
- Azacitidine (Vidaza) (PDF) (CP.PHAR.387)
- Baloxavir Marboxil (Xofluza) (PDF) (CP.PMN.185)
- Bedaquiline (Sirturo) (PDF) (CP.PMN.212)
- Belantamab Mafodotin (Blenrep) (PDF) (CP.PHAR.469)
- belinostat (PDF) (CP.PHAR.311)
- Belzutifan (Welireg) (PDF) (CP.PHAR.553)
- Bempedoic Acid (Nexletol), Bempedoic Acid/Ezetimibe (Nexlizet) (PDF) (CP.PMN.237)
- bendamustine (PDF) (CP.PHAR.307)
- Benign Prostatic Hyperplasia (BPH) Agents-PDE5 Inhibitors (PDF) (WA.PHAR.44)
- Benznidazole (PDF) (CP.PMN.90)
- Benzyl Alcohol (Ulesfia) (PDF) (CP.PMN.202)
- Berdazimer (Zelsuvmi) (PDF) (CP.PMN.293)
- Betaine (Cystadane) (PDF) (CP.PHAR.143)
- Betamethasone Dipropionate Spray (Sernivo) (PDF) (CP.PMN.182)
- Bevacizumab (Avastin) (PDF) (CP.PHAR.93)
- Bexarotene (Targretin Capsules, Gel) (PDF) (CP.PHAR.75)
- Bezlotoxumab (PDF) (CP.PHAR.300)
- Bimatoprost Implant (Durysta) (PDF) (CP.PHAR.486)
- Binimetinib (Mektovi) (PDF) (CP.PHAR.50)
- Blinatumomab (PDF) (CP.PHAR.312)
- Bone Density Regulators (PDF) (WA.PHAR.45)
- Bortezomib (Velcade) (PDF) (CP.PHAR.410)
- Brands with Generic Equivalents (PDF) (WA.PHAR.65)
- Bremelanotide (Vyleesi) (PDF) (CP.PHAR.434)
- Brentuximab (PDF) (CP.PHAR.303)
- Brexanolone (Zulresso) (PDF) (CP.PHAR.417)
- Brexpiprazole (PDF) (CP.PMN.68)
- Brimonidine Tartrate (Mirvaso) (PDF) (CP.PMN.192)
- Brolucizumab-dbll (Beovu) (PDF) (CP.PHAR.445)
- Budesonide (Eohilia, Uceris) (PDF) (CP.PMN.294)
- Budesonide (Tarpeyo) (PDF) (CP.PHAR.572)
- (MAT) Buprenorphine Products (PDF) (WA.PHAR.62)
- Cabazitaxel (Jevtana) (PDF) (CP.PHAR.316)
- Calcifediol (Rayaldee) (PDF) (CP.PMN.76)
- Calcipotriene/Betamethasone Dipropionate Foam (Enstilar) (PDF) (CP.PMN.181)
- Cannabidiol (Epidiolex) (PDF) (CP.PMN.164)
- Capecitabine (Xeloda) (PDF) (CP.PHAR.60)
- Carbamazepine ER (Equetro) (PDF) (CP.PMN.137)
- Carbidopa/Levodopa ER Capsules (Rytary), Enteral Suspension (Duopa), IR Tablets (Dhivy) (PDF) (CP.PMN.238)
- Cardiovascular Agents-Sinus Node Inhibitors (PDF) (WA.PHAR.46)
- carfilzomib (PDF) (CP.PHAR.309)
- Celecoxib (Celebrex, Elyxyb) (PDF) (CP.PMN.122)
- Cemiplimab-rwlc (Libtayo) (PDF) (CP.PHAR.397)
- Cenobamate (Xcopri) (PDF) (CP.PMN.231)
- cetuximab (PDF) (CP.PHAR.317)
- Chenodiol (Chenodal) (PDF) (CP.PMN.239)
- Chlorambucil (Leukeran) (PDF) (CP.PHAR.554)
- Chloramphenicol Sodium Succinate (PDF) (CP.PHAR.388)
- Cholic Acid (Cholbam) (PDF) (CP.PHAR.390)
- Chronic GI Motility Agents (PDF) (WA.PHAR.47)
- Ciclopirox (Penlac) (PDF) (CP.PMN.24)
- Cipaglucosidase Alfa-atga + Miglustat (Pombiliti + Opfolda) (PDF) (CP.PHAR.567)
- Ciprofloxacin/Dexamethasone (Ciprodex) (PDF) (CP.PMN.248)
- Ciprofloxacin/Fluocinolone (Otovel) (PDF) (CP.PMN.249)
- Cladribine (Mavenclad) (PDF) (CP.PHAR.422)
- Clascoterone (Winlevi) (PDF) (CP.PMN.257)
- Clobazam (Onfi) (PDF) (CP.PMN.54)
- Clomipramine (Anafranil) (PDF) (CP.PMN.197)
- Clozapine orally disintegrating tablet (Fazaclo) (PDF) (CP.PMN.12)
- CNS Stimulants (PDF) (CP.PMN.92)
- Cobimetinib (Cotellic) (PDF) (CP.PHAR.380)
- Colchicine (PDF) (CP.PMN.123)
- Colesevelam (WelChol) (PDF) (CP.PMN.250)
- Conjugated Estrogens/Bazedoxifene (Duavee) (PDF) (CP.PMN.258)
- Continuous Glucose Monitoring (PDF) (WA.PHAR.133)
- copanlisib (PDF) (CP.PHAR.357)
- Corticosteroids - Deflazacort (Emflaza) (PDF) (WA.PHAR.135)
- Corticosteroids for Ophthalmic Injection (Dextenza, Iluvien, Ozurdex, Retisert, Xipere, Yutiq) (PDF) (CP.PHAR.385)
- Corticotropin (H.P. Acthar Gel) (PDF) (CP.PHAR.168)
- Cosyntropin (Cortrosyn) (PDF) (CP.PHAR.203)
- Cyclosporine (Cequa, Restasis, Verkazia) (PDF) (CP.PMN.48)
- Cysteamine Ophthalmic (Cystaran, Cystadrops) (PDF) (CP.PMN.130)
- Cystic Fibrosis Agents (Oral) (PDF) (WA.PHAR.48)
- Cytokine and CAM Antagonists (PDF) (WA.PHAR.49)
- Cytomegalovirus Immune Globulin (Cytogam) (PDF) (CP.PHAR.277)
- Dabigatran (Pradaxa) (PDF) (CP.PMN.49)
- Dabrafenib (Tafinlar) (PDF) (CP.PHAR.239)
- Dalteparin (PDF) (CP.PHAR.225)
- Daprodustat (Jesduvroq) (PDF) (CP.PHAR.628)
- daptomycin (PDF) (CP.PHAR.351)
- Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro) (PDF) (CP.PHAR.310)
- Darolutamide (Nubeqa) (PDF) (CP.PHAR.435)
- daunorubicin cytarabine (PDF) (CP.PHAR.352)
- DaxibotulinumtoxinA-lanm (Daxxify) (PDF) (CP.PHAR.651)
- Decitabine-Cedazuridine (Inqovi) (PDF) (CP.PHAR.479)
- deferasirox (PDF) (CP.PHAR.145)
- deferiprone (PDF) (CP.PHAR.147)
- deferoxamine (PDF) (CP.PHAR.146)
- Degarelix Acetate (Firmagon) (PDF) (CP.PHAR.170)
- Delafloxacin (Baxdela) (PDF) (CP.PMN.115)
- Denosumab (Prolia, Xgeva), Denosumab-bbdz (Jubbonti, Wyost) (PDF) (CP.PHAR.58)
- Dermatologics Acne Products- Isotretinoin (PDF) (WA.PHAR.121)
- Desmopressin (DDAVP, Stimate) (PDF) (CP.PHAR.214)
- Dexrazoxane (Zinecard Totect) (PDF) (CP.PHAR.418)
- Dextromethorphan/Bupropion (Auvelity) (PDF) (CP.PMN.284)
- Dextromethorphan-Quinidine (PDF) (CP.PMN.93)
- Diabetic Test Strip Quantity Limit - Not Receiving Insulin (PDF) (CP.PMN.151)
- Diazepam Nasal Spray (Valtoco) (PDF) (CP.PMN.216)
- Dichlorphenamide (Keveyis) (PDF) (CP.PMN.261)
- Diclofenac (Pennsaid) (PDF) (CP.PMN.274)
- Dimethyl Fumarate (Tecfidera), Diroximel Fumarate (Vumerity), Monomethyl Fumarate (Bafiertam) (PDF) (CP.PHAR.249)
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (PDF) (CP.PMN.03)
- Dolasetron (Anzemet) (PDF) (CP.PMN.141)
- Dornase alfa (Pulmozyme) (PDF) (CP.PHAR.212)
- Dostarlimab-gxly (Jemperli) (PDF) (CP.PHAR.540)
- Doxepin (Silenor) (PDF) (CP.PMN.175)
- Doxycycline Hyclate (Acticlate, Doryx), Doxycycline (Oracea) (PDF) (CP.PMN.79)
- Droxidopa (Northera) (PDF) (CP.PMN.17)
- Duplicate SSRI SNRI Therapy (PDF) (CP.PMN.60)
- Durvalumab (Imfinzi) (PDF) (CP.PHAR.339)
- Dutasteride (Avodart, Jalyn) (PDF) (CP.PMN.128)
- Duvelisib (Copiktra) (PDF) (CP.PHAR.400)
- Edoxaban (Savaysa) (PDF) (CP.PMN.227)
- Efinaconazole (Jublia) (PDF) (CP.PMN.25)
- Eflornithine (Iwilfin) (PDF) (CP.PHAR.670)
- Elacestrant (Orserdu) (PDF) (CP.PHAR.623)
- Elafibranor (Iqirvo) (PDF) (CP.PHAR.688)
- Elagolix (Orilissa) (PDF) (CP.PHAR.136)
- Elotuzumab (Empliciti) (PDF) (CP.PHAR.308)
- Elranatamab-bcmm (Elrexfio) (PDF) (CP.PHAR.652)
- enasidenib (PDF) (CP.PHAR.363)
- Encorafenib (Braftovi) (PDF) (CP.PHAR.127)
- Enfortumab Vedotin-ejfv (Padcev) (PDF) (CP.PHAR.455)
- Enoxaparin (PDF) (CP.PHAR.224)
- Entrectinib (Rozlytrek) (PDF) (CP.PHAR.441)
- Enzalutamide (PDF) (CP.PHAR.106)
- Epcoritamab-bysp (Epkinly) (PDF) (CP.PHAR.634)
- EPSDT Benefit for Pediatric Members (PDF) (WA.CP.PMN.234)
- Epinephrine (EpiPen and EpiPen Jr) Quanity Limit Override (PDF) (CP.PMN.144)
- Epoprostenol (Flolan, Veletri) (PDF) (CP.PHAR.192)
- Erdafitinib (Balversa) (PDF) (CP.PHAR.423)
- eribulin Mesylate (PDF) (CP.PHAR.318)
- Erwinia Asparaginase (Erwinaze) (PDF) (CP.PHAR.301)
- Esketamine (Spravato) (PDF) (CP.PMN.199)
- Estradiol Vaginal Ring (Femring) (PDF) (CP.PMN.263)
- Etelcalcetide (Parsabiv) (PDF) (CP.PHAR.379)
- Etrasimod (Velsipity) (PDF) (CP.PHAR.661)
- Everolimus (PDF) (CP.PHAR.63)
- Experimental Technologies (PDF) (WA.CP.MP.36)
- Fam-trastuzumab Deruxtecan-nxki (Enhertu) (PDF) (CP.PHAR.456)
- Faricimab-svoa (Vabysmo) (PDF) (CP.PHAR.581)
- Fecal Microbiota, Live-jslm (Rebyota) (PDF) (CP.PHAR.613)
- Fecal Microbiota Spores, Live-brpk (Vowst) (PDF) (CP.PHAR.632)
- Fedratinib (Inrebic) (PDF) (CP.PHAR.442)
- Fenfluramine (Fintepla) (PDF) (CP.PMN.246)
- Ferric Carboxymaltose (Injectafer) (PDF) (CP.PHAR.234)
- Ferric Derisomaltose (Monoferric) (PDF) (CP.PHAR.480)
- Ferric Gluconate (Ferrlecit) (PDF) (CP.PHAR.166)
- Ferric Maltol (Accrufer) (PDF) (CP.PMN.213)
- Ferric Pyrophosphate (Triferic, Triferic Avnu) (PDF) (CP.PHAR.624)
- Ferumoxytol (Feraheme) (PDF) (CP.PHAR.165)
- Fezolinetant (Veozah) (PDF) (CP.PMN.289)
- Fill Limits (PDF) (WA.PHAR.141)
- Finerenone (Kerendia) (PDF) (CP.PMN.266)
- Fingolimod (Gilenya) (PDF) (CP.PHAR.251)
- Flibanserin (Addyi) (PDF) (CP.PHAR.446)
- Fluorouracil Cream (Tolak) (PDF) (CP.PMN.165)
- Fluticasone Propionate (Xhance) (PDF) (CP.PMN.95)
- Fondaparinux (PDF) (CP.PHAR.226)
- Fruquintinib (Fruzaqla) (PDF) (CP.PHAR.666)
- Fulvestrant (Faslodex Injection) (PDF) (CP.PHAR.424)
- Furosemide (Furoscix) (PDF) (CP.PHAR.608)
- Futibatinib (Lytgobi) (PDF) (CP.PHAR.604)
- Gabapentin ER (Gralise, Horizant) (PDF) (CP.PMN.240)
- gemtuzumab ozogamicin (PDF) (CP.PHAR.358)
- Gender Affirming Treatments for Specialist Review (PDF) (WA.PHAR.142)
- Gepirone (Exxua) (PDF) (CP.PMN.292)
- Glasdegib (Daurismo) (PDF) (CP.PHAR.413)
- Glatiramer Acetate (Copaxone, Glatopa) (PDF) (CP.PHAR.252)
- Glaucoma Agents (PDF) (CP.PMN.286)
- Glofitamab-gxbm (Columvi) (PDF) (CP.PHAR.636)
- Glycopyrronium (Qbrexza) (PDF) (CP.PMN.177)
- Goserelin Acetate (Zoladex) (PDF) (CP.PHAR.171)
- Gout Agents (PDF) (WA.PHAR.40)
- Granisetron (Sancuso, Sustol) (PDF) (CP.PMN.74)
- Growth Hormone Agents (PDF) (WA.PHAR.50)
- Halobetasol Propionate Lotion 0.05% (Ultravate) (PDF) (CP.PMN.180)
- Halobetasol Propionate/Tazarotene (Duobrii) (PDF) (CP.PMN.208)
- Hematopoietic Agents Erythropoiesis-Stimulating Agents (ESAs) (PDF) (WA.PHAR.71)
- Hematopoietic Agents Granulocyte Colony Stimulating Factors (G-CSF) (PDF) (WA.PHAR.72)
- Hematopoietic Agents Thrombopoieses (TPO) Stimulating Proteins (PDF) (WA.PHAR.73)
- Hemin (Panhematin) (PDF) (CP.PHAR.181)
- Hormone Therapy for Gender Dysphoria (PDF) (WA.PHAR.104)
- Hyaluronate Derivatives (PDF) (CP.PHAR.05)
- Hydroxyurea (Siklos) (PDF) (CP.PMN.193)
- Ibrance (palbociclib) (PDF) (CP.PHAR.125)
- Ibuprofen/Famotidine (Duexis) (PDF) (CP.PMN.120)
- Idelalisib (Zydelig) (PDF) (CP.PHAR.133)
- Iloperidone (Fanapt) (PDF) (CP.PMN.32)
- Imetelstat (Rytelo) (PDF) (CP.PHAR.690)
- Immune Globulins (PDF) (CP.PHAR.103)
- Immune Modulators- Thalidomide Analogs (PDF) (WA.PHAR.140)
- Immunization coverage (PDF) (CP.PHAR.28)
- Inclisiran (Leqvio) (PDF) (CP.PHAR.568)
- IncobotulinumtoxinA (Xeomin) (PDF) (CP.PHAR.231)
- Infigratinib (Truseltiq) (PDF) (CP.PHAR.547)
- Inhaled Agents for Asthma and COPD (PDF) (CP.PMN.259)
- inotuzumab ozogamicin (PDF) (CP.PHAR.359)
- Insulin Delivery Systems (V-Go, Omnipod, InPen) (PDF) (CP.PHAR.534)
- Interferon beta-1a (Avonex, Rebif) (PDF) (CP.PHAR.255)
- Interferon beta-1b (Betaseron, Extavia) (PDF) (CP.PHAR.256)
- Intrathecal Baclofen (Gablofen, Lioresal) (PDF) (CP.PHAR.149)
- Iobenguane I-131 (Azedra) (PDF) (CP.PHAR.459)
- Ipilimumab (Yervoy) (PDF) (CP.PHAR.319)
- irinotecan Liposome (PDF) (CP.PHAR.304)
- Iron sucrose (Venofer) (Acthar Gel) (PDF) (CP.PHAR.167)
- Isatuximab-irfc (Sarclisa) (PDF) (CP.PHAR.482)
- Isavuconazonium (Cresemba) (PDF) (CP.PMN.154)
- Isotretinoin (PDF) (CP.PMN.143)
- Istradefylline (Nourianz) (PDF) (CP.PMN.217)
- Itraconazole (Sporanox, Onmel) (PDF) (CP.PMN.124)
- Ivermectin (Stromectol, Sklice) (PDF) (CP.PMN.269)
- Ivosidenib (Tibsovo) (PDF) (CP.PHAR.137)
- Ixazomib (PDF) (CP.PHAR.302)
- Ketamine (Ketalar) (PDF) (CP.PMN.296)
- Ketorolac Nasal Spray (Sprix) (PDF) (CP.PMN.282)
- Korlym (mifepristone) (PDF) (CP.PHAR.101)
- Lacosamide (Vimpat) (PDF) (CP.PMN.155)
- Lactic Acid/Citric Acid/Potassium Bitartrate (Phexxi) (PDF) (CP.PMN.251)
- Lanreotide (Somatuline Depot) (PDF) (CP.PHAR.391)
- Larotrectinib (Vitrakvi) (PDF) (CP.PHAR.414)
- Lasmiditan (Reyvow) (PDF) (CP.PMN.218)
- Lefamulin (Xenleta) (PDF) (CP.PMN.219)
- Lenacapavir (Sunlenca) (PDF) (CP.PHAR.622)
- Letermovir (Prevymis) (PDF) (CP.PHAR.367)
- Leucovorin Injection (PDF) (CP.PHAR.393)
- Leuprolide Acetate (Eligard, Fensolvi, Lupaneta Pack, Lupron Depot, Lupron Depot-Ped) (PDF) (CP.PHAR.173)
- Levodopa Inhalation Powder (Inbrija) (PDF) (CP.PMN.267)
- Levoleucovorin (Fusilev) (PDF) (CP.PHAR.151)
- lidocaine transdermal (PDF) (CP.PMN.08)
- Lifileucel (Amtagvi) (PDF) (CP.PHAR.598)
- Lindane Lotion Shampoo (PDF) (CP.PMN.09)
- Linezolid (Zyvox) (PDF) (CP.PMN.27)
- Lofexidine (Lucemyra) (PDF) (CP.PMN.152)
- Lomustine (Gleostine) (PDF) (CP.PHAR.507)
- Loncastuximab Tesirine-lpyl (Zynlonta) (PDF) (CP.PHAR.539)
- Loteprednol etabonate (Eysuvis) (PDF) (CP.PMN.260)
- Lotilaner (Xdemvy) (PDF) (CP.PMN.291)
- Luliconazole Cream (Luzu) (PDF) (CP.PMN.166)
- Lumateperone (Caplyta) (PDF) (CP.PMN.232)
- Lurasidone (Latuda) (PDF) (CP.PMN.50)
- Lurbinectedin (Zepzelca) (PDF) (CP.PHAR.500)
- Mannitol (Bronchitol) (PDF) (CP.PHAR.518)
- Margetuximab-cmkb (Margenza) (PDF) (CP.PHAR.522)
- Maribavir (Livtencity) (PDF) (CP.PMN.271)
- Mavacamten (Camzyos) (PDF) (CP.PMN.272)
- Mecamylamine (Vecamyl) (PDF) (CP.PMN.136)
- Mecasermin (PDF) (CP.PHAR.150)
- Mechlorethamine Gel (Valchlor) (PDF) (CP.PHAR.381)
- Megestrol Acetate 125 mg/mL Oral Suspension (Megace ES) (PDF) (CP.PMN.179)
- Melphalan flufenamide (Pepaxto) (PDF) (CP.PHAR.535)
- Melphalan (Hepzato) (PDF) (CP.PHAR.653)
- Mercaptopurine (Purixan) (PDF) (CP.PHAR.447)
- Metformin ER (Fortamet, Glumetza) (PDF) (CP.PMN.72)
- Methadone (Dolophine) (PDF) (WA.PHAR.20)
- Methotrexate (Otrexup, Rasuvo, Xatmep) (PDF) (CP.PHAR.134)
- Metoclopramide (Gimoti) (PDF) (CP.PMN.252)
- Midostaurin (Rydapt) (PDF) (CP.PHAR.344)
- Migraine Products Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist (PDF) (WA.PHAR.64)
- Milnacipran (Savella) (PDF) (CP.PMN.125)
- Minocycline ER (Solodyn, Ximino) and Microspheres (Arestin), Foam (Zilxi) (PDF) (CP.PMN.80)
- Minocycline Micronized Foam (Amzeeq) (PDF) (CP.PMN.242)
- Mirvetuximab soravatansine-gynx (Elahere) (PDF) (CP.PHAR.617)
- Mitomycin for Pyelocalyceal Solution (Jelmyto) (PDF) (CP.PHAR.495)
- Mitoxantrone (Novantrone) (PDF) (CP.PHAR.258)
- Mogamulizumab-kpkc (Poteligeo) (PDF) (CP.PHAR.139)
- Momelotinib (Ojjaara) (PDF) (CP.PHAR.654)
- Mometasone Furoate (Sinuva) (PDF) (CP.PHAR.448)
- Mosunetuzumab-axgb (Lunsumio) (PDF) (CP.PHAR.618)
- Motixafortide (Aphexda) (PDF) (CP.PHAR.655)
- Movement Disorder Agents Valbenazine (Ingrezza) (PDF) (WA.PHAR.139)
- Moxetumomab pasudotox-tdfk (Lumoxiti) (PDF) (CP.PHAR.398)
- Multiple Sclerosis Agents-Dalfampridine (Ampyra) (PDF) (WA.PHAR.52)
- Multiple Sclerosis- Ocrelizumab (Ocrevus) (PDF) (WA.PHAR.69)
- Musculoskeletal Therapy Agents - Carisoprodol (PDF) (WA.PHAR.130)
- Nabumetone Double-Strength (Relafen DS) (PDF) (CP.PMN.287)
- Nadofaragene Firadenovec-vncg (Adstiladrin) (PDF) (CP.PHAR.461)
- Nafarelin Acetate (Synarel) (PDF) (CP.PHAR.174)
- Nalmefene (Opvee) (PDF) (CP.PHAR.638)
- Naproxen/Esomeprazole (Vimovo) (PDF) (CP.PMN.117)
- (MAT) Naltrexone Products (PDF) (WA.PHAR.63)
- Natalizumab (Tysabri) (PDF) (CP.PHAR.259)
- Naxitamab-gqgk (Danyelza) (PDF) (CP.PHAR.523)
- necitumumab (PDF) (CP.PHAR.320)
- Neomycin/Fluocinolone Cream (Neo-Synalar) (PDF) (CP.PMN.167)
- Netupitant and Palonosetron (Akynzeo) (PDF) (CP.PMN.158)
- Neuromuscular Agents - Lupus Agents (PDF) (WA.PHAR.136)
- Nifurtimox (Lampit) (PDF) (CP.PMN.256)
- Niraparib (Zejula) (PDF) (CP.PHAR.408)
- Niraparib and Abiraterone Acetate (Akeega) (PDF) (CP.PHAR.645)
- Nirogacestat (Ogsiveo) (PDF) (CP.PHAR.671)
- Nirsevimab-alip (Beyfortus) (PDF) (CP.PHAR.614)
- Nivolumab (PDF) (CP.PHAR.121)
- Nivolumab and Relatlimab-rmbw (Opdualag) (PDF) (CP.PHAR.588)
- No Coverage Criteria (PDF) (CP.PMN.255)
- No Coverage Criteria/Off-Label Use Policy (PDF) (CP.PMN.53)
- Nogapendekin Alfa Inbakicept-pmln (Anktiva) (PDF) (CP.PHAR.684)
- Non-Calcium Phosphate Binders (PDF) (CP.PMN.04)
- Non-Contracted Drugs (PDF) (WA.PHAR.126)
- Non-Formulary and Non-Preferred Drug Not Otherwise Specified (PDF) (WA.PHAR.61)
- Non-Preferred Blood Glucose Monitors/Test Strips (PDF) (CP.PMN.215)
- Obeticholic (PDF) (CP.PHAR.287)
- obinutuzumab (PDF) (CP.PHAR.305)
- Octreotide Acetate (Sandostatin, Sandostatin LAR Depot) (PDF) (CP.PHAR.40)
- Ofatumumab (Arzerra, Kesimpta) (PDF) (CP.PHAR.306)
- olanzapine la inj (PDF) (CP.PHAR.292)
- Olanzapine (Zyprexa Zydis®) (PDF) (CP.PMN.29)
- Olanzapine/Samidorphan (Lybalvi) (PDF) (CP.PMN.265)
- Olaparib (PDF) (CP.PHAR.360)
- Olutasidenib (Rezlidhia) (PDF) (CP.PHAR.615)
- Omadacycline (Nuzyra) (PDF) (CP.PMN.188)
- Omecetaxine (Synribo) (PDF) (CP.PHAR.108)
- Omega-3-Acid Ethyl Esters (Lovaza) (PDF) (CP.PMN.52)
- OnabotulinumtoxinA (Botox) (PDF) (CP.PHAR.232)
- Oncology Agents- Androgen Biosynthesis Inhibitors- Abiraterone (PDF) (WA.PHAR.138)
- Ondansetron (Zuplenz) (PDF) (CP.PMN.45)
- Ophthalmic Immunomodulators-Lifitegrast 5% Ophthalmic Solution (PDF) (WA.PHAR.58)
- Ophthalmic Riboflavin (Photrexa, Photrexa Viscous) (PDF) (CP.PHAR.536)
- Opicapone (Ongentys) (PDF) (CP.PMN.245)
- Ospemifene (Osphena) (PDF) (CP.PMN.168)
- Overactive Bladder Agents (PDF) (CP.PMN.198)
- Oxymetazoline (Rhofade, Upneeq) (PDF) (CP.PMN.86)
- Ozanimod (Zeposia) (PDF) (CP.PHAR.462)
- Ozenoxacin (Xepi) (PDF) (CP.PMN.119)
- Paclitaxel protein-bound (Abraxane) (PDF) (CP.PHAR.176)
- Pacritinib (Vonjo) (PDF) (CP.PHAR.583)
- Paliperidone Long-Acting Injections (Invega Hafyera, Invega Sustenna, Invega Trinza) (PDF) (CP.PHAR.291)
- Palivizumab (Synagis) (PDF) (CP.PHAR.16)
- Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep) (PDF) (CP.PMN.226)
- panitumumab (PDF) (CP.PHAR.321)
- Panobinostat (Farydak) (PDF) (CP.PHAR.382)
- Parathyroid hormone (Natpara) (PDF) (CP.PHAR.282)
- Paricalcitol Injection (PDF) (CP.PHAR.270)
- pasireotide (PDF) (CP.PHAR.332)
- Patiromer (Veltassa) (PDF) (CP.PMN.205)
- Peanut Allergen Powder-dnfp (Palforzia) (PDF) (CP.PMN.220)
- pegaspargase (PDF) (CP.PHAR.353)
- Peginterferon beta-1a (Plegridy) (PDF) (CP.PHAR.271)
- Pegvisomant (Somavert) (PDF) (CP.PHAR.389)
- Pembrolizumab (Keytruda) (PDF) (CP.PHAR.322)
- Pemetrexed (Alimta) (PDF) (CP.PHAR.368)
- Pemigatinib (Pemazyre) (PDF) (CP.PHAR.496)
- Pentosan Polysulfate Sodium (Elmiron) (PDF) (CP.PMN.276)
- Perampanel (Fycompa) (PDF) (CP.PMN.156)
- Perfluorohexyloctane (Miebo) (PDF) (CP.PMN.290)
- Perindopril/Amlodipine (Prestalia) (PDF) (CP.PMN.174)
- Pertuzumab (Perjeta) (PDF) (CP.PHAR.227)
- Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (Phesgo) (PDF) (CP.PHAR.501)
- Pilocarpine (Vuity) (PDF) (CP.PMN.270)
- Pimavanserin (Nuplazid) (PDF) (CP.PMN.140)
- Plerixafor (PDF) (CP.PHAR.323)
- Polatuzumab Vedotin-piiq (Polivy) (PDF) (CP.PHAR.433)
- Ponesimod (Ponvory) (PDF) (CP.PHAR.537)
- pralatrexate (PDF) (CP.PHAR.313)
- Prasterone (Intrarosa) (PDF) (CP.PMN.99)
- Preferred Stimulants for Adults (PDF) (WA.PHAR.132)
- Pregabalin (Lyrica, Lyrica CR) (PDF) (CP.PMN.33)
- Pretomanid (PDF) (CP.PMN.222)
- Progesterone (Crinone, Endometrin, Milprosa) (PDF) (CP.PMN.243)
- Propranolol HCl Oral Solution (Hemangeol) (PDF) (CP.PMN.58)
- Protein C Concentrate, Human (Ceprotin) (PDF) (CP.PHAR.330)
- Proton Pump Inhibitors (PPI) (PDF) (WA.PHAR.81)
- Pulmonary Arterial Hypertension (PAH) Agents (Oral and Inhalation) (PDF) (WA.PHAR.55)
- Pulmonary Fibrosis Agents (PDF) (WA.PHAR.57)
- Quantity Limit Overrides (PDF) (CP.PMN.59)
- Quetiapine ER (Seroquel XR) (PDF) (CP.PMN.64)
- Quinine Sulfate (Qualaquin) (PDF) (CP.PNM.262)
- Quizartinib (Vanflyta) (PDF) (CP.PHAR.646)
- Ramelteon (Rozerem) (PDF) (CP.PMN.173)
- Ramucirumab (Cyramza) (PDF) (CP.PHAR.119)
- Ranibizumab (Byooviz, Cimerli, Lucentis, Susvimo) (PDF) (CP.PHAR.186)
- Ranolazine (Ranexa) (PDF) (CP.PMN.34)
- Regorafenib (PDF) (CP.PHAR.107)
- Relugolix (Orgovyx) (PDF) (CP.PHAR.529)
- Repotrectinib (Augtyro) (PDF) (CP.PHAR.667)
- Resmetirom (Rezdiffra) (PDF) (CP.PHAR.647)
- Respiratory Agents- Misc Alpha-Proteinase Inhibitor (Human) (PDF) (WA.PHAR.68)
- Respiratory syncytial virus vaccine (Abrysvo) (PDF) (CP.PHAR.658)
- Retifanlimab-dlwr (Zynyz) (PDF) (CP.PHAR.629)
- Ribavirin (Rebetol, Ribasphere) (PDF) (CP.PHAR.141)
- Ribociclib (Kisqali), Ribociclib/Letrozole (Kisqali Femara) (PDF) (CP.PHAR.334)
- Rifabutin (Mycobutin) (PDF) (CP.PMN.223)
- Rifamycin (Aemcolo) (PDF) (CP.PMN.196)
- Rifapentine (Priftin) (PDF) (CP.PMN.05)
- RimabotulinumtoxinB (Myobloc) (PDF) (CP.PHAR.233)
- Risperidone LA Inj (PDF) (CP.PHAR.293)
- Rituximab (Rituxan, Riabni, Ruxience, Truxima, Rituxan Hycela) (PDF) (CP.PHAR.260)
- Rivaroxaban (Xarelto) (PDF) (CP.PMN.247)
- Rivastigmine (Exelon®) (PDF) (CP.PMN.101)
- roflumilast (PDF) (CP.PMN.46)
- Rolapitant (Varubi) (PDF) (CP.PMN.102)
- Romidepsin (Istodax) (PDF) (CP.PHAR.314)
- Romosozumab-aqqg (Evenity) (PDF) (CP.PHAR.428)
- Ropeginterferon Alfa-2b-njft (BESREMi) (PDF) (CP.PHAR.570)
- Rucaparib (Rubraca) (PDF) (CP.PHAR.350)
- Rufinamide (Banzel) (PDF) (CP.PMN.157)
- Rukobia (fostemsavir) (PDF) (CP.PHAR.516)
- Ruxolitinib (Jakafi, Opzelura) (PDF) (CP.PHAR.98)
- Sacituzumab Govitecan-hziy (Trodelvy) (PDF) (CP.PHAR.475)
- Safinamide (Xadago) (PDF) (CP.PMN.113)
- Sarecycline (Seysara) (PDF) (CP.PMN.189)
- Sargramostim (PDF) (CP.PHAR.295)
- Secnidazole (PDF) (CP.PMN.103)
- Second Opinion Network (SON) Review (PDF) (WA.PHAR.14)
- Selinexor (Xpovio) (PDF) (CP.PHAR.431)
- Selumetinib (PDF) (CP.PHAR.464)
- Sensipar (PDF) (CP.PHAR.61)
- Setmelanotide (Imcivree) (PDF) (CP.PHAR.491)
- Siltuximab (Sylvant) (PDF) (CP.PHAR.329)
- Siponimod (Mayzent) (PDF) (CP.PHAR.427)
- Sirolimus Protein-Bound Particles (Fyarro) (PDF) (CP.PHAR.574)
- Sleep Disorder Agents - Hetlioz (tasimelteon) (PDF) (WA.PHAR.137)
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (PDF) (CP.PMN.14)
- Sodium thiosulfate (Pedmark) (PDF) (CP.PHAR.610)
- Sodium Zirconium Cyclosilicate (Lokelma) (PDF) (CP.PMN.163)
- Sonidegib (Odomzo) (PDF) (CP.PHAR.272)
- Sorafenib (Nexavar) (PDF) (CP.PHAR.69)
- Sotatercept (Winrevair) (PDF) (CP.PHAR.657)
- Sotorasib (Lumakras) (PDF) (CP.PHAR.549)
- Spesolimab-sbzo (Spevigo) (PDF) (CP.PHAR.606)
- Stiripentol (Diacomit) (PDF) (CP.PMN.184)
- Substance Use Disorders (SUDs)- Buprenorphine extended-release injection (Sublocade) (PDF) (WA.PHAR.108)
- Sunitinib (Sutent) (PDF) (CP.PHAR.73)
- Suvorexant (Belsomra) (PDF) (CP.PMN.109)
- Sylatron (peginterferon alfa-2b) (PDF) (CP.PHAR.89)
- Tafasitamab-cxix (Monjuvi) (PDF) (CP.PHAR.508)
- Talazoparib (Talzenna) (PDF) (CP.PHAR.409)
- Talimogene laherepvec (Imlygic) (PDF) (CP.PHAR.542)
- Talquetamab-tgvs (Talvey) (PDF) (CP.PHAR.649)
- Tapinarof (Vtama) (PDF) (CP.PMN.283)
- Tarlatamab-dlle (Imdelltra) (PDF) (CP.PHAR.685)
- Tazarotene (Arazlo, Fabior, Tazorac) (PDF) (CP.PMN.244)
- Tavaborole (Kerydin) (PDF) (CP.PMN.105)
- Tazemetostat (PDF) (CP.PHAR.452)
- Tebentafusp-tebn (Kimmtrak) (PDF) (CP.PHAR.575)
- Teclistamab-cqyv (Tecvayli) (PDF) (CP.PHAR.611)
- Tedizolid (Sivextro) (PDF) (CP.PMN.62)
- Telotristat ethyl (Xermelo) (PDF) (CP.PHAR.337)
- Tesamorelin (PDF) (CP.PHAR.109)
- Temsirolimus (Torisel) (PDF) (CP.PHAR.324)
- Tenapanor (Ibsrela) (PDF) (CP.PMN.224)
- Tenofovir Alafenamide Fumarate (Vemlidy) (PDF) (CP.PMN.268)
- Tepotinib (Tepmetko) (PDF) (CP.PHAR.530)
- Teriflunomide (PDF) (CP.PHAR.262)
- Tezepelumab-ekko (Tezspire) (PDF) (CP.PHAR.576)
- Therapies for COVID-19 (PDF) (WA.PHAR.127)
- Thioguanine (Tabloid) (PDF) (CP.PHAR.437)
- Thyrotropin alfa (PDF) (CP.PHAR.95)
- Tislelizumab-jsgr (Tevimbra) (PDF) (CP.PHAR.687)
- Tisotumab Vedotin-tftv (Tivdak) (PDF) (CP.PHAR.561)
- Tivozanib (Fotivda) (PDF) (CP.PHAR.538)
- Tolvaptan (Jynarque) (PDF) (CP.PHAR.27)
- Topiramate Extended-Release (Qudexy XR, Trokendi XR) (PDF) (CP.PMN.281)
- Topotecan (Hycamtin) (PDF) (CP.PHAR.64)
- Toremifene (Fareston) (PDF) (CP.PMN.126)
- Toripalimab-tpzi (Loqtorzi) (PDF) (CP.PHAR.668)
- Trabectedin (Yondelis) (PDF) (CP.PHAR.204)
- Tralokinumab-ldrm (Adbry) (PDF) (CP.PHAR.577)
- Trametinib (Mekinist) (PDF) (CP.PHAR.240)
- Transmucosal Fentanyl Products (PDF) (WA.PHAR.80)
- Trastuzumab Biosimilars Trastuzumab-Hyaluronidase (PDF) (CP.PHAR.228)
- Travoprost Implant (iDose TR) (PDF) (CP.PHAR.672)
- Tremelimumab-actl (Imjudo) (PDF) (CP.PHAR.612)
- Triamcinolone ER Injection (PDF) (CP.PHAR.371)
- Triclabendazole (Egaten) (PDF) (CP.PMN.207)
- Trientine (Cuvrior, Syprine) (PDF) (CP.PHAR.438)
- Trifarotene (Aklief) (PDF) (CP.PMN.225)
- Trifluridine, Tipiracil (Lonsurf) (PDF) (CP.PHAR.383)
- Triptorelin Pamoate (Trelstar, Triptodur) (PDF) (CP.PHAR.175)
- Ublituximab-xiiy (Briumvi) (PDF) (CP.PHAR.621)
- Ulcer Therapy Combinations (PDF) (CP.PMN.277)
- Umbralisib (Ukoniq) (PDF) (CP.PHAR.531)
- Vadadustat (Vafseo) (PDF) (CP.PHAR.677)
- Valrubicin (Valstar) (PDF) (CP.PHAR.439)
- Vamorolone (Agamree) (PDF) (CP.PHAR.659)
- Varenicline (Tyrvaya) (PDF) (CP.PMN.273)
- Vemurafenib (Zelboraf®) (PDF) (CP.PHAR.91)
- Venetoclax (Venclexta) (PDF) (CP.PHAR.129)
- Verteporfin (Visudyne) (PDF) (CP.PHAR.187)
- Vigabatrin (PDF) (CP.PHAR.169)
- Vincristine Sulfate Liposome Injection (Marqibo) (PDF) (CP.PHAR.315)
- Vismodegib (Erivedge) (PDF) (CP.PHAR.273)
- Vorinostat (PDF) (CP.PHAR.83)
- Voxelotor (Oxbryta) (PDF) (CP.PHAR.451)
- Xiaflex™ (PDF) (CP.PHAR.82)
- Zavegepant (Zavzpret) (PDF) (CP.PHAR.630)
- Ziv-aflibercept (Zaltrap) (PDF) (CP.PHAR.325)
- Zoledronic Acid (Reclast, Zometa) (PDF) (CP.PHAR.59)
- Zolpidem Tartrate (Edluar, Zolpimist) (PDF) (CP.PMN.172)
- Zuranolone (Zurzuvae) (PDF) (CP.PHAR.650)
Payment Policies
Health care claims payment policies are guidelines used to assist in administering payment rules based on generally accepted principles of correct coding. They are used to help identify whether health care services are correctly coded for reimbursement. Each payment rule is sourced by a generally accepted coding principle. They include, but are not limited to claims processing guidelines referenced by the Centers for Medicare and Medicaid Services (CMS), Publication 100-04, Claims Processing Manual for physicians/non-physician practitioners, the CMS National Correct Coding Initiative policy manual (procedure-to-procedure coding combination edits and medically unlikely edits), Current Procedural Technology guidance published by the American Medical Association (AMA) for reporting medical procedures and services, health plan clinical policies based on the appropriateness of health care and medical necessity, and at times state-specific claims reimbursement guidance.
All policies found in the Coordinated Care Payment Policy Manual apply with respect to Coordinated Care members. Policies in the Coordinated Care Payment Policy Manual may have either a Coordinated Care or a “Centene” heading. In addition, Coordinated Care may from time to time employ a vendor that applies payment policies to specific services; in such circumstances, the vendor’s guidelines may also be used to determine whether a service has been correctly coded. Other policies (e.g., clinical policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Payment Policy Manual is payable by Coordinated Care.
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
Ambetter Payment Policies
For Ambetter information, please visit our Ambetter website.
Medicaid Payment Policies
- 1-Day Payment Window (PDF) (WA.PP.500)
- Add on Code Billed Without Primary Code (PDF) (CC.PP.030)
- Assistant Surgeon (PDF) (CC.PP.029)
- Bilateral Procedures (PDF) (CC.PP.037)
- Cerumen Removal (PDF) (CC.PP.008)
- Clean Claims (PDF) (CC.PP.021)
- Coding Overview (PDF) (CC.PP.011)
- Concert Laboratory Payment Policy (PDF) (CG.CC.PP.01) - effective 10/1/2024
- Cosmetic Procedures (PDF) (CC.PP.024)
- Distinct Procedural Modifiers (PDF) (CC.PP.020)
- Duplicate Primary Code Billing (PDF) (CC.PP.044)
- E&M Medical Decision-Making (PDF) (CC.PP.051)
- EM Bundling Edits (PDF) (CC.PP.010)
- Genetic and Molecular Testing Services (Version A) (PDF) (CG.PP.551) - effective 10/1/2024
- Global Maternity Billing (PDF) (CC.PP.016)
- Hospital Visit Codes Billed with Labs (PDF) (CC.PP.023)
- Infectious Disease: Dermatologic Lab Testing (PDF) (CG.CP.MP.03) - effective 11/1/2024
- Infectious Disease: Gastroenterologic Lab Testing (PDF) (CG.CP.MP.04) - effective 11/1/2024
- Infectious Disease: Genitourinary Lab Testing (PDF) (CG.CP.MP.07) - effective 11/1/2024
- Infectious Disease: Multisystem Lab Testing (PDF) (CG.CP.MP.02) - effective 11/1/2024
- Infectious Disease: Primary Care & Preventive Lab Screening (PDF) (CG.CP.MP.05) - effective 11/1/2024
- Infectious Disease: Respiratory Lab Testing (PDF) (CG.CP.MP.01) - effective 11/1/2024
- Infectious Disease: Vector-borne and Tropical Diseases Lab Testing (PDF) (CG.CP.MP.06) - effective 11/1/2024
- Inpatient Consultation (PDF) (CC.PP.038)
- Inpatient Only Procedures (PDF) (CC.PP.018)
- IV Hydration (PDF) (CC.PP.012)
- Leveling of Emergency Room Services (PDF) (CC.PP.053)
- Maximum Units (PDF) (CC.PP.007)
- Moderate Conscious Sedation (PDF) (CC.PP.015)
- Modifier -25 clinical validation (PDF) (CC.PP.013)
- Modifier -59 clinical validation (PDF) (CC.PP.014)
- Modifier DOS Validation (PDF) (CC.PP.034)
- Modifier to Procedure Code Validation (PDF) (CC.PP.028)
- Multiple CPT Code Replacement (PDF) (CC.PP.033)
- Multiple Diagnostic Cardiovascular Procedure (MDCP) (PDF) (CC.PP.065)
- NCCI Unbundling (PDF) (CC.PP.031)
- Never Paid Events (PDF) (CC.PP.017)
- New Patient (PDF) (CC.PP.036)
- Outpatient Consultation (PDF) (CC.PP.039)
- Pelvic and Transabdominal US (PDF) (CC.PP.061)
- Physician Visit Codes Billed with Labs (PDF) (CC.PP.019)
- Place of Service Mismatch (PDF) (CC.PP.063)
- Post-Operative Visits (PDF) (CC.PP.042)
- Pre-Operative Visits (PDF) (CC.PP.041)
- Professional Component (PDF) (CC.PP.027)
- Provider Preventable Readmissions (PDF) (WA.PP.501)
- Pulse Oximetry (PDF) (CC.PP.025)
- Renal Hemodialysis (PDF) (CC.PP.067)
- Same Day Visits (PDF) (CC.PP.040)
- Sepsis Diagnosis (PDF) (CC.PP.073)
- Severe Malnutrition (PDF) (CC.PP.145)
- Skilled Nursing Facility Leveling (PDF) (CC.PP.206)
- Sleep Studies Place of Services (PDF) (CC.PP.035)
- Status "B" Bundled Services (PDF) (CC.PP.046)
- Status P Bundled Services (PDF) (CC.PP.049)
- Supplies Billed on Same Day As Surgery (PDF) (CC.PP.032)
- Transgender Related Services (PDF) (CC.PP.047)
- Unbundled Surgical Procedures (PDF) (CC.PP.045)
- Unbundled Professional Services (PDF) (CC.PP.043)
- Unlisted Procedure Codes (PDF) (CC.PP.009)
- Wheelchair Accessories (PDF) (CC.PP.502)
Policy Revision Summary (Clinical)
Policy Number | Policy Title | Revision Notes |
WA.CP.MP.54 | Hospice Services | Annual review. References reviewed and updated. Background updated per corporate policy. Initial Request Section II. B. and Subsequent Requests Section II. A. verbiage updated to align with HCA billing guidelines. Subsequent Requests section I. verbiage updated to reflect the length election periods per HCA billing guidelines. Subsequent Requests section III. removed length of certification period. Section III. Not Medically Necessary services, added reference to WAC for concurrent care < age 21. Levels of Care Definitions and Certification Periods sections removed. Covered Services section I. verbiage updated and section O. added to align with HCA billing guidelines. Non-covered Services section updated to list services not included in the hospice daily rate per HCA billing guidelines. Removed G0299 from coding table. |
CP.MP.51 | Reduction Mammoplasty and Gynecomastia Surgery | Annual review. Verbiage updated in criteria I.A.4.b. Removed criteria I.A.4.c. and d. Criteria updated to include mammogram requirement for members/enrollees < 40 years of age with symptoms of breast cancer or high-risk factors for breast cancer in what is now I.A.4.c.i.through iii. Clarifying language added to Criteria II.A.2. Criteria II.B.3. updated to include clarifying language and to include gynecomastia that persists for more than three months after unsuccessful medical treatment for pathological gynecomastia. Criteria II.B.4. updated to include clarifying language. References reviewed and updated. |
Policy Number | Policy Title | Revision Notes |
CP.MP.93 | Bone-anchored Hearing Aid | Annual review. Updated criteria in I.C. to specify “is consistent with the FDA indications for the requested device”. Added “(provided that the nerve is functional)” to I.F.1. Minor updates made to I.F4. and the policy statements in II. and III. Reference reviewed and updated. |
WA.CP.MP.532 | Chronic Migraine and Tension-Type Headaches | New policy |
CP.MP.129 | Fetal Surgery in Utero for Prenatally Diagnosed Malformations | Annual review. Description updated with no impact to criteria. Under I.A. added “with treatment including”. Added criteria to I.A.1.-I.A.2. to include: Correction via a minimally invasive approach; SCT resection when meeting all of the following: Fetuses with high-risk SCT and hydrops developing at a gestational age earlier than appropriate for delivery and neonatal care (eg. 28-32 weeks gestation); Does not have the following contraindications: Type III or IV Altman-type tumors; Severe placentomegaly; Maternal cervical shortening. Removed indication I.F.5. Normal fetal karyotype. Quantified criteria I.F.5.c. to include (≥30 degrees). Added criteria I.G. Fetal endoscopic tracheal occlusion (FETO) for congenital diaphragmatic hernia (CDH) when all of the following criteria are met: Severe left-sided CDH; Severe pulmonary hypoplasia defined as a quotient of the observed-to-expected lung-to-head ratios of less than 25%; Gestational age ≤ 30 weeks. Removed III.A. Open or endoscopic fetal surgery for congenital diaphragmatic hernia (CDH), including temporary tracheal occlusion. References reviewed and updated. Reviewed by external specialist. |
WA.CP.MP.531 | Imaging for Breast Cancer Screening | New policy |
WA.CP.BH.522 | Nonpharmacological Treatments for Depression | New policy |
CP.MP.182 | Short Inpatient Hospital Stay | Updated to policy description. Changed policy statement I. to “an inpatient level of care for hospital stays of less than three midnights is medically necessary…”. Added “in use by the applicable plan” to criteria I.B. Added “inpatient” criteria I.F. Updated policy statement II. to “inpatient hospital stays lasting three midnights and beyond…”. |
WA.CP.MP.534 | Upright Positional MRI | New policy |
WA.CP.MP.12 | Vagus Nerve Stimulation | Consolidated Section II and III to more closely mirror the corporate policy. Corrected criteria II.J. to read "essential tremor". |
WA.CP.MP.527 | Vitamin D Testing | Annual review. References verified. |
Policy Number | Policy Title | Revision Notes |
CP.MP.108 | Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-Thalassemia | Annual review. Added note at end of Description regarding criteria related to Casgevy. Reformatted all notes in policy description. Reformatted Criteria I.A. to specify one of the following. Minor format changes in Criteria I. with no impact to criteria. References reviewed and updated. |
WA.CP.MP.530 | Bone Morphogenic Proteins for Use in Spinal Fusion | New policy |
WA.CP.MP.516 | Carotid Artery Stenting | Annual review. References updated. CPT codes updated to include 37217, 37246, and 37247 per billing guidelines. Section I. C. removed as criteria and changed to informational note defining “high risk” per HTA criteria. Section II verbiage updated to align with HCA Billing Guideline requirement for accredited facility. |
CP.MP.31 | Cosmetic and Reconstructive Procedures | Annual review. Added note to see MC.CP.MP.31 for Medicare health plans. Updated criteria numbering so that I.A.2.a. is now I.A.3. Added criteria to I.A.2. to include in an area that affects eyesight. Under I.A.3. replaced “standard” with “conservative. Moved notes about health plan-adopted nationally recognized decision support criteria and gender dysphoria to Description. Removed note regarding prophylactic mastectomy with BRCA mutation. Minor rewording in Background with no impact to criteria. References reviewed and updated. Reviewed by external specialist. |
CP.MP.203 | Diaphragmatic/Phrenic Nerve Stimulation | Annual review. Criteria I. updated to include the Spirit Diaphragm Pacing Transmitter. Background updated to include information regarding full FDA approval of the Spirit Diaphragm Pacing Transmitter. References reviewed and updated. Reviewed by external specialist. |
CP.MP.107 | Durable Medical Equipment (DME) and Orthotics and Prosthetics Guidelines | Updated verbiage in Newborn Care Equipment, Breast Pumps for inclusivity. Added new criteria section titled Lumbar-Sacral Orthotics (LSO) and included codes L0450, L0452, L0454, L0455, L0456, L0457, L0458, L0460, L0462, L0464, L0466, L0467, L0468, L0469, L0470, L0472, L0480, L0482, L0484, L0486, L0488, L0490, L0491, L0492, L0621, L0622, L0623, L0624, L0625, L0626, L0627, L0628, L0629, L0630, L0631, L0632, L0633, L0634, L0635, L0636, L0637, L0638, L0639, L0640, L0643, L0648, L0649, L0650, L0651, L0700, L0710, L0999, L1000, L1001, L1005. Renamed original “Spinal Orthotics” criteria “Other Spinal Orthotics”. Updated manual wheelchair initial request criteria A., A.2. and 4., B.1. and 2., and removed C. Reformatted and updated manual wheelchair replacement request criteria. Deleted codes E1091 and K0009. Reviewed by internal specialist. |
CP.MP.184 | Home Ventilators | Annual review. Added note for corresponding Medicare policy. Updated all policy statements to indicate "non-Medicare" health plans. In I.A.1 changed "both" to "one" of the following and added "taken while member/enrollee was stable (not in acute respiratory failure)". Removed criteria for BiPAP failure and contraindications in sections I and II, and replaced with criteria requiring documentation that "member/enrollee could not be appropriately treated with a RAD" and "non-invasive home ventilator will not be used to provide RAD or CPAP therapy...". Removed criteria in I.A.1.a. and b. for members/enrollees < 18 years. In 1.A.1a. updated PaCO2 > to greater than or equal to. In I.C.1 updated BMI > than 30 to greater than or equal to 30. In 1.C.2 added "at baseline". Added criteria I.C.3. "Hypoventilation has been documented by polysomnography and other conditions are not considered the primary cause of hypoventilation..." Removed medical necessity criteria I.D. for home ventilators for treatment failure of BiPAP. In II.B. replaced "medical records document improvement..." with II.B.1. and 2. "Documentation supports: Ongoing benefits... and "non-invasive home ventilator will not be used to provide RAD or CPAP therapy...". Minor rewording throughout policy with no clinical significance. References reviewed and updated. External specialist review. |
CP.MP.180 | Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea | Policy being archived due to lack of benefit. |
CP.MP.250 | Lantidra (donislecel): Allogeneic pancreatic islet cellular therapy | Annual review. References reviewed and updated. Reviewed by external specialist. |
CG.CP.MP.01 | ID Respiratory Lab Testing | New policy |
CG.CP.MP.02 | ID Multisystem Lab Testing | New policy |
CG.CP.MP.03 | ID Dermatologic Lab Testing | New policy |
CG.CP.MP.04 | ID Gastroenterologic Lab Testing | New policy |
CG.CP.MP.05 | ID Primary Care Preventive Lab Testing | New policy |
CG.CP.MP.06 | ID Vector-Borne and Tropical Diseases Lab Testing | New policy |
CG.CP.MP.07 | ID Genitourinary Lab Testing | New policy |
WA.CP.MP.69 | Intensity-Modulated Radiotherapy | Removed section I. A. (Age <= 18 years) and section I. C. Added section I. B. documentation of critical structure and re-worded section I. A. to align with HCA Billing Guidelines. References reviewed and updated. |
CP.MP.167 | Intradiscal Steroid Injections for Pain Management | Annual review. References reviewed and updated. Reviewed by external specialist. |
WA.CP.MP.507 | Oral Enteral Nutrition | Annual review. References updated. |
CP.MP.202 | Orthognathic Surgery | Annual review. Updated Criteria I.A.1.b. from greater than 4 mm to 4 mm or greater. Updated Criteria I.A.2.c. to include irritation of buccal or lingual soft tissues of the opposing arch. Added clarifying language to Criteria I.A.3.b. References reviewed and updated. Reviewed by internal specialist and external specialist. |
WA.CP.MP.194 | Osteogenic Stimulation | New policy |
CP.MP.109 | Panniculectomy | Annual review. References reviewed and updated. |
CP.MP.138 | Pediatric Heart Transplant | Annual review. Updated description and background with no clinical significance. References reviewed and updated. |
CP.MP.150 | Phototherapy for Neonatal Hyperbilirubinemia | Annual review. Rearranged verbiage regarding infants ≥ 38 weeks gestation in Criteria I. and I.A. Removed “Term” verbiage in Criteria I.B. References reviewed and updated. Reviewed by external specialist. |
CP.MP.87 | Therapeutic Utilization of Inhaled Nitric Oxide | Corrected May revision log entry to include, removed criteria I.A.“iNO will be administered via endotracheal tube or tracheostomy,” and, updated oxygen index from ≥ 25 to > 20 in criteria I.A.6. Added additional indication I.B.1.a.3) right ventricular failure. |
WA.CP.BH.200 | Transcranial Magnetic Stimulation (TMS) for TRMD | Added contraindications |
CP.MP.169 | Trigger Point Injections for Pain Management | Annual review. Removed “with or without radiographic guidance” language in Criteria I.A. Criteria I.A.1.a. updated to state “myofascial pain.” Removed Criteria II.C. regarding location of trigger point injection in the neck, shoulder, and/or back. Background updated with no impact to criteria. References reviewed and updated. Reviewed by internal specialist and external specialist. |
WA.CP.MP.12 | Vagus Nerve Stimulation | Policy reimplemented |
WA.CP.MP.522 | Varicose Vein Treatment | Annual review. References reviewed and updated. Background updated with no impact on criteria. Section I. A. a. reflux measurement removed to align with billing guidelines. Section I. C. removed criteria and added note for reviewer to utilize CP.MP.146 for procedures 36482, 36483. Section II. removed. Codes 36482, 36483 and 0524T removed from coding table. Code 37799 removed from note regarding ligation/stripping procedures. |
Policy Number | Policy Title | Revision Notes |
CP.BH.500 | Behavioral Health Treatment Documentation Requirements | Annual Review. No changes to criteria. Background updated. References reviewed and updated |
CP.MP.14 | Cochlear Implant Replacements | Annual review. Updated description and background with no clinical significance. Coding reviewed, updated description for L8623. References reviewed and updated. |
CP.MP.94 | Clinical Trials | Annual review. Updated policy statement in I. to include “Centene Advanced Behavioral Health”. References reviewed and updated. |
WA.CP.MP.514 | Extracorporeal Membrane Oxygenation Therapy | Annual review. References updated. |
CP.MP.137 | Fecal Incontinence Treatments | Annual review. Minor rewording in Description and in Background with no impact on criteria. References reviewed and updated. |
CP.MP.40 | Gastric Electrical Stimulation | Annual review. Updated description and background with no clinical significance. Added I.A. "Member/enrollee is ≥ 18 years of age". Updated I.B. to include "diabetic or" in describing type of gastroparesis. Updates made to CPT code descriptions. References reviewed and updated. |
CP.MP.132 | Heart-Lung Transplant | Annual review. Added indication to criteria I.A.1.j. Expanded criteria I.C.1. to I.C.1.a. through c. Removed contraindication I.C.17., active peptic ulcer disease. References reviewed and updated. |
CP.MP.141 | Non-Myeloablative Allogenic Stem Cell Transplants | Annual review. Removed Hodgkin’s lymphoma from Criteria I.A.9. per updated National Comprehensive Cancer Network (NCCN) recommendations. Added Criteria I.A.13.e. to include polycythemia vera. Updated Criteria I.B.4.b. from diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 50% of predicted value to DLCO ≤ 60% of predicted value. Removed absolute contraindications in Criteria I.C. References reviewed and updated. Reviewed by internal specialist and reviewed by external specialist. |
CP.MP.249 | Omisirge (omidubicel): Nicotinamide-modified allogeneic hematopoietic progenitor cell therapy | Annual review. Added note to policy to refer to MC.CP.MP.249 for Medicare criteria. Added “non-Medicare” to health plans in Policy/Criteria I. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist. |
CP.MP.49 | Physical, Occupational and Speech Therapy Services | Annual review. Minor rewording in Criteria I.G.1., Criteria I.G.2., Criteria II.A., and Criteria II.A.10. Updated formatting in Criteria III.A.2. with no impact on criteria. Minor rewording in Background with no impact on criteria. Reviewed by external specialist. |
WA.CP.MP.185 | Skin and Soft Tissue Substitutes for Chronic Wounds | Annual review. References reviewed and updated. Reviewed by external specialist. Policy description updated with no impact on criteria. Section V corrected to reflect “all indications in section I-III.” HCPCS covered and non-covered coding tables removed and added note for providers to contact Coordinated Care for current coding implications and coverage determinations. |
CP.MP.127 | Total Artificial Heart | Annual review. References reviewed and updated. Reviewed by external specialist. |
Policy Number | Policy Title | Revision Notes |
CP.MP.114 | Disc Decompression Procedures | Annual review. Removed “unilateral” for radiculopathy in Criteria I.C.1. Updated muscle strength score in Criteria I.C.1.a. from < 3 to ≤ 3. Updated muscle strength score in Criteria I.C.1.b. from 3 or 4 to 4. Added “within the last year” for conservative therapy in Criteria I.C.1.b.ii. Updated physical therapy from ≥ six weeks to ≥ four weeks in Criteria I.C.1.b.ii.a). Updated activity modification from ≥ six weeks to ≥ four weeks in Criteria I.C.1.b.ii.b). Updated Criteria I.C.1.b.ii.c) to specify one of the following: 1) NSAID or acetaminophen ≥ 3 weeks unless contraindicated or not tolerated 2) Epidural steroid injection. Removed “unilateral” for radiculopathy in Criteria I.C.2. Updated physical therapy from ≥ six weeks to ≥ four weeks in Criteria I.C.2.a. Updated activity modification from ≥ six weeks to ≥ four weeks in Criteria I.C.2.b. Updated Criteria I.C.2.c. to specify one of the following: i. NSAID or acetaminophen ≥ 3 weeks unless contraindicated or not tolerated ii. Epidural steroid injection. References reviewed and updated. Reviewed by external specialist. |
CP.MP.115 | Discography | Annual review. Background updated with no impact on criteria. References reviewed and updated. |
CP.MP.58 | Intestinal and Multivisceral Transplant | Annual review. Expanded criteria under II.A.4. to include (e.g. opioid dependency, or pseudo-obstruction). Updated contraindication under II.B.3. Glomerular filtration rate < 40 mL/min/1.73m2 to <30mL/min/1.73m2. Expanded contraindication under II.B.4.a-II.B.4.c. to include CD4 cell count >200 cells/mm3; Absence of active AIDS-defining opportunistic infection (unless treated efficaciously or prevented, can be included on the heart transplant waiting list) or malignancy; Member/enrollee is currently on effective ART (antiretroviral therapy). References reviewed and updated. Reviewed by external specialist. |
CP.MP.244 | Liposuction of Lipedema | Annual review. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist. |
CP.MP.116 | Lysis of Epidural Lesions | Annual review. Updated description and background with no clinical significance. References reviewed and updated. Reviewed by external specialist. |
CP.MP.24 | Multiple Sleep Latency Testing | Annual review. References reviewed and updated. Reviewed by external specialist. |
WA.CP.MP.518 | Negative Pressure Wound Therapy for Home Use | Annual review. References reviewed and updated. Section I. A. i. and ii. diagnoses of seroma and wound dehiscence removed. |
CP.MP.120 | Pediatric Liver Transplant | Annual review. Added HIV points a. - c., under I.C.2. Minor edits to Background with no effect on criteria. References reviewed and updated. |
CP.MP.188 | Pediatric Oral Function Therapy | Annual review. References reviewed and updated. Reviewed by external specialist. |
CP.MP.210 | Repair of Nasal Valve Compromise | Annual review. Background updated with no impact to criteria. References reviewed and updated. |
CP.MP.87 | Therapeutic Utilization of Inhaled Nitric Oxide | Annual review. Condensed criteria statement II. to, "while the medical literature predominantly does not support the use of inhaled nitric oxide (iNO) in premature infants < 34 weeks gestational age at birth, requests for initiation of iNO therapy in these infants may be reviewed on a case-by-case basis with consideration of the criteria for premature newborns ≥ 34 weeks gestational age at birth in section I.” References reviewed and updated. Reviewed by external specialist. |
WA.CP.MP.509 | Upper GI Endoscopy for GERD | Annual review. References reviewed and updated. CPT codes 43237, 43238 and 43242 added per billing guidelines. Description and section I. updated to reflect diagnostic endoscopy per billing guidelines. Removed section II. header and use of InterQual guidelines; converted policy to billing guidelines/HTA only. |
August 2024 – Genetic Testing | ||
Policy Number | Policy Title | Revision Notes |
V2.2024 | CG Aortopathies and Connective Tissue Disorders | See policy posted on Website |
V2.2024 | CG Cardiac Disorders | See policy posted on Website |
V2.2024 | CG Dermatologic Conditions | See policy posted on Website |
V2.2024 | CG Epilepsy Neurodegenerative and Neuromuscular Conditions | See policy posted on Website |
V2.2024 | CG Exome and Genome Sequencing for DX of Genetic Disorders | See policy posted on Website |
V2.2024 | CG Eye Disorders | See policy posted on Website |
V2.2024 | CG Gastroenterologic Disorders Non-cancerous | See policy posted on Website |
V2.2024 | CG General Approach to Genetic Testing | See policy posted on Website |
V2.2024 | CG Hearing Loss | See policy posted on Website |
V2.2024 | CG Hematologic Conditions Non-cancerous | See policy posted on Website |
V2.2024 | CG Hereditary Cancer Susceptibility | See policy posted on Website |
V2.2024 | CG Immune Autoimmune and Rheumatoid Disorders | See policy posted on Website |
V2.2024 | CG Kidney Disorders | See policy posted on Website |
V2.2024 | CG Lung Disorders | See policy posted on Website |
V2.2024 | CG Metabolic Endocrine Mitochondrial Disorders | See policy posted on Website |
V2.2024 | CG Multisystem Inherited Disorders, Intellectual Disability and Developmental Delay | See policy posted on Website |
WA.CP.MP.230 | Genetic Testing Multisystem Inherited Disorders, Intellectual Disability and Developmental Delay | See policy posted on Website |
V2.2024 | CG Non-Invasive Prenatal Screening | See policy posted on Website |
WA.CP.MP.231 | Genetic Testing Non-Invasive Prenatal Screening (NIPS) | See policy posted on Website |
V2.2024 | CG Oncology Algorithmic Testing | See policy posted on Website |
V2.2024 | CG Oncology Cancer Screening | See policy posted on Website |
V2.2024 | CG Oncology Circulating Tumor DNA Tumor Cells Liquid Biopsy | See policy posted on Website |
V2.2024 | CG Oncology Cytogenetic Testing | See policy posted on Website |
V2.2024 | CG Oncology Molecular Analysis Solid Tumors & Hematologic Malignancies | See policy posted on Website |
V2.2024 | CG Pharmacogenetics | See policy posted on Website |
WA.CP.MP.232 | Genetic Testing Pharmacogenetics | New policy |
V2.2024 | CG Preimplantation Genetic Testing | See policy posted on Website |
V2.2024 | CG Prenatal and Preconception Carrier Screening | See policy posted on Website |
V2.2024 | CG Prenatal Diagnosis Pregnancy Loss | See policy posted on Website |
V2.2024 | CG Skeletal Dysplasia Rare Bone Disorders | See policy posted on Website |
Policy Number | Policy Title | Revision Notes |
WA.CP.MP.519 | Administrative Days | References reviewed and updated. Removed note requiring providers to request administrative days. Section I. subsections D. and E. and section IV. subsections E. and F. facility requirements for discharge planning removed to align with WAC. Billing section updated to include other service categories that may be billed per revenue codes in the billing guidelines. Section II. E. added to reflect additional newborn administrative day services per the billing guidelines. Added references for acute PM&R. Description updated to clarify the process for social admissions per WAC 182-550-4550. WAC reference removed from description and replaced with Washington State Health Care Authority. Section I. approval requirements changed from “all” to “A. and B. or C.” per the HCA billing guidelines. Section IV. D. removed. |
WA.CP.BH.521 | Behavioral Health Wraparound Support (BHWS) | Annual review. Renamed policy from “Behavioral Health Personal Care Services” in preparation for July contract change. Updated Description. Policy criteria rewritten to match new contract language. Reference updated. Changed policy number to WA.CP.BH.521 from WA.CP.MP.521 to reflect behavioral health nature of the policy. |
WA.CP.MP.513 | Cardiac Stents | Annual review. References reviewed and updated. CPT codes added per HCA Billing Guidelines: 92933, 92934, 92937, 92938, 92941, 92943 and 92944. |
WA.CP.BH.529 | Community Behavioral Health Support - Supportive Supervision (CBHS) | New policy. |
CP.MP.101 | Donor lymphocyte infusion | Annual review. Minor rewording in Description with no impact on Criteria. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist. |
WA.CP.MP.504 | Elective Deliveries Before 39 Weeks | Annual review. References updated. Added reference for WAC 182-500-0030. Removed all ICD-10 diagnosis codes with instruction to reference the current Joint Commission document for a complete list of diagnosis codes for Conditions Possibly Justifying Elective Delivery. |
CP.MP.248 | Facility Based Sleep Studies for Obstructive Sleep Apnea | Annual review. Updated description and included “Notes”. Added non-Medicare to all policy statements. Added superscript citations throughout policy. In I.B.8.a. added "documentation". Updated I.B.8.a.i. to "Moderate to severe, chronic pulmonary disease". Removed criteria I.B.8.a.i.a) and b). Updated I.B.8.a.ii. to "Congestive heart failure...". Updated I.B.8.a.v. to "Concern for significant non-respiratory sleep disorder(s)...". Added I.B.8.a.vi "Hypoventilation syndrome". Updated I.B.8.b.ii to "Daytime sleepiness...". Added I.B.8.b.ii.a "Habitual loud snoring". Removed I.B.8.b.iv. "Significant oxygen desaturation...". Updated III.A. to "Meets criteria in section I...". Removed III.C and D. for central sleep apnea. References reviewed and updated. Internal and external specialist reviewed. |
CP.MP.62 | Hyperhidrosis treatments | Annual review. Minor rewording of pharmacy policy title (in description). Changed order of criteria. Added criteria point III.I. regarding counseling on risks. Background updated with no clinical significance. Removed CPT codes 64802 through 64823. References reviewed and updated. Reviewed by external specialist. |
WA.CP.MP.27 | Hyperbaric Oxygen Therapy | Annual review. References reviewed and updated. Section II. G. wording updated to align with billing guidelines. Section I. multiple punctuation corrections, no impact on criteria. |
CP.MP.173 | Implantable Intrathecal or Epidural Pain Pump | Annual review. Restructured and reformatted criteria section. In I.B. and II.B. added contraindications to include known allergies to materials in the implant; active alcohol or drug abuse, including but not limited to opioid addiction and intravenous drug abuse, diagnosis of dementia or psychosis; active systemic infection, active infection at the site of implantation. Background updated with no impact to criteria. References reviewed and updated. |
CP.MP.243 | Implantable Loop Recorder (Implantable Cardiac Monitor) | Annual review. Added criteria III. to include requests for replacement implantable loop recorders. Background updated with no impact to criteria. References reviewed and updated. Reviewed by external specialist. |
WA.CP.BH.528 | Intensive Behavioral Supportive Supervision (IBSS) | Added Tiering Guidelines. Changed “IBSS Modifier” to “ILOS Modifier” |
CP.MP.57 | Lung Transplantation | Annual review. Updated I.C.2. from GFR < 40 mL/min/1.73m2 to GFR < 30 mL/min/1.73m2. Expanded I.C.9. with qualifying criteria for members who are HIV positive. Updated I.D.2.a.1. from FEV1<25% to FEV1<30%. Background updated with no impact to criteria. References reviewed and updated. |
CP.MP.170 | Nerve Blocks and Neurolysis for Pain Management | Annual review completed. Minor rewording with no clinical significance. References reviewed and updated. |
CP.MP.82 | NICU Apnea Bradycardia Guidelines | Annual review. Minor rewording throughout criteria with no impact on criteria. Added clarifying language to Criteria I.A.1.c. and updated oxygen saturation percentage from < 85% to ≤ 85%. Updated wording in Criteria I.A.2.a. for clarity and flow. Updated Criteria I.A.2.b. to include verbiage for significantly reducing the severity and duration of bradycardia or apnea events. Updated Criteria I.A.3.d. to include that parents or caregivers agree with the plan of care. Added Criteria I.A.3.e. regarding the home situation being assessed and deemed adequate. Expanded information on CPR requirement in Note section at end of Criteria. Updated Note section at end of Criteria to include when additional observation days may be needed. Minor rewording in Background with no impact on criteria. References reviewed and updated. Criteria I.A.1.c., Criteria I.A.2.a., and Criteria I.A.2.b. reviewed by internal specialist |
CP.MP.246 | Pediatric Kidney Transplant | Annual review. Updated contraindication I.B.2, adding a. through c. References reviewed and updated. Reviewed by external specialist. |
CP.MP.182 | Short Inpatient Hospital Stay | Annual review. Updated criteria I.A. from 2023 inpatient only link to 2024 link. Updated description and background with no clinical significance. References reviewed and updated. |
WA.CP.MP.22 | Stereotactic Body Radiation Therapy | New policy |
CP.MP.22 | Stereotactic Body Radiation Therapy | Annual review. Updated cancer staging in Criteria I.A. to align with National Comprehensive Cancer Network (NCCN) guidelines. Criteria II.C. updated to include details regarding positive clinical indications regarding stable systemic disease, Karnofsky Performance Score, survival expectations, and Eastern Cooperative Oncology Group (ECOG) Performance Status to align with ASTRO 2022 Model Policy for SRS. Criteria II.J. added to include trigeminal neuralgia and select cases of medically refractory epilepsy, movement disorders such as Parkinson’s disease and essential tremor, and hypothalamic hamartomas to align with 2022 ASTRO Model Policy for SRS. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist. |
Policy Number | Policy Title | Revision Notes |
WA.CP.MP.501 | Continuous Glucose Monitor | Annual review. References updated. Updated section I. and Background to include reference to HCA Billing Guidelines. |
WA.CP.MP.50 | Drugs of Abuse: Definitive Testing | Annual review. Updated policy statements in I. and II.. Updated background with no clinical significance. References reviewed and updated. Internal specialist review. |
WA.CP.MP.36 | Experimental Technologies | Annual review. Added updated background with no clinical significance. References reviewed and updated. Removed definition of Humanitarian Use Device (HUD) from section 11. a. and updated language to correspond with WAC 182-501-0165. |
CP.MP.62 | Hyperhidrosis Treatments | Added note regarding the normal line of medical therapy back into policy after erroneously removing during January 2024 annual policy review. |
CP.MP.250 | Lantidra (donislecel): Allogeneic pancreatic islet cellular therapy | Added note to description regarding Medicare policy version. Removed maximum age requirement from Criteria I.A. |
WA.CP.MP.505 | Microprocessor-Controlled Lower Limb Prosthetics | Annual review. References updated. Removed HCPCS L2006 and L5973 per previous revision. |
CP.MP.102 | Pancreas Transplantation | Annual review. Expanded criteria I.B. to I.B.a. through c. Updated description and background with no clinical significance. Coding reviewed. References reviewed and updated. Reviewed by external specialist |
WA.CP.MP.503 | Private Duty Nursing | Annual review. References reviewed and updated. Section III. A. updated reference HCA Billing Guidelines. Section III. C. wording updated to include EPSDT WAC and clarified hours for limitation extension/EPSDT requests. EPSDT WAC added to references. Struck references to social/economic factors. |
CP.MP.162 | Tandem Transplant | Annual review. Added a. through c. to I.B.10.; a. CD4 cell count > 200 cells/mm3, b. Absence of active AIDS-defining opportunistic infection, and c. Member/enrollee is currently on effective ART (antiretroviral therapy). Updated background info on testicular cancer with no impact on criteria. References reviewed and updated. |
WA.CP.MP.517 | Testosterone Testing | Annual review. References updated. |
CP.MP.163 | Total Parenteral Nutrition and Intradialytic Parenteral Nutrition | Annual review completed. Minor rewording in Criteria section with no clinical significance. Background updated with no impact to criteria. References reviewed and updated. External specialist reviewed. |
WA.CP.MP.520 | Tympanostomy Tubes | Annual review. References updated. |
WA.CP.MP.46 | Ventricular Assist Devices | Annual review. References reviewed and updated. Minor rewording in description with no impact on criteria. Added FDA approval requirement to Sections I and II per billing guidelines. Updated section I. A. language for clarity, no impact on criteria. |
Policy Number | Policy Title | Revision Notes |
---|---|---|
CP.MP.186 | Burn Surgery | Annual review. Added criteria II.C. that burn must be deep partial-thickness or full-thickness. Added used according to FDA indications to II.D.3. References reviewed and updated. Reviewed by internal specialist |
WA.CP.MP.200 | Transcranial Magnetic Stimulation for Treatment Resistant Major Depression | Revised to reflect updated Billing Guideline and revised HTA |
CP.MP.186 | Psychological Testing | Archived |
Policy Number | Policy Title | Revision Notes |
CP.BH.104 | Applied Behavioral Analysis | Annual review. Replaced all instances of “DSM-5” with “DSM-5 TR”. Added requirement for a comprehensive diagnostic evaluation to have been conducted within the past five years in I.A.1. Added Social Skills Improvement System (SSIS) as an additional skill assessment option in I.E.1.b.ii.e. In I.E.,2.b. deleted “comprehensive.” Deleted I.E.,2.b.ii.e). and replaced it as a “note” under I.2.b.ii.d). In I.E.2.c.vi. deleted “in the home or community activities.” Added I.E.2.f.i. “Behavioral health outpatient services” to the list. Added statement to I.E.3.b. “Assessments are performed consistent with criteria in I.E.1. b.” Rearranged criteria point in I.E.3 for clarity. In II.A. added statement “… and generally involve a gradual step-down in services.” In II.C. Removed the statements “Services may be appropriate for discontinuation and/or transfer to alternative or less intrusive levels of care.” Removed ICD 10 chart. Updated description and background with no clinical significance. References reviewed and updated. Annual review. Replaced all instances of “DSM-5” with “DSM-5 TR”. Added requirement for a comprehensive diagnostic evaluation to have been conducted within the past five years in I.A.1. Added Social Skills Improvement System (SSIS) as an additional skill assessment option in I.E.1.b.ii.e. In I.E.,2.b. deleted “comprehensive.” Deleted I.E.,2.b.ii.e). and replaced it as a “note” under I.2.b.ii.d). In I.E.2.c.vi. deleted “in the home or community activities.” Added I.E.2.f.i. “Behavioral health outpatient services” to the list. Added statement to I.E.3.b. “Assessments are performed consistent with criteria in I.E.1. b.” Rearranged criteria point in I.E.3 for clarity. In II.A. added statement “… and generally involve a gradual step-down in services.” In II.C. Removed the statements “Services may be appropriate for discontinuation and/or transfer to alternative or less intrusive levels of care.” Removed ICD 10 chart. Updated description and background with no clinical significance. References reviewed and updated. |
CP.BH.105 | Applied Behavioral Analysis Documentation Requirements | New Policy |
CP.MP.186 | Burn Surgery | Annual review. Added criteria II.C. that burn must be deep partial-thickness or full-thickness. Added used according to FDA indications to II.D.3. References reviewed and updated. Reviewed by internal specialist. |
CP.MP.105 | Digital EEG Analysis | Added new for 2024 ICD-10 codes G40.C11 and G40.C19 to ICD-10 coding table. |
WA.CP.MP.515 | Fecal Microbiota Transplantation | Annual review. References updated. |
WA.CP.MP.130 | Fertility Preservation | Annual review. Reference updated. |
CP.MP.129 | Fetal Surgery in Utero for Prenatally Diagnosed Malformations | Updated criteria I.G.6. to maternal body mass index of ≥ 40 and added supportive references. |
CP.MP.136 | Home Birth | Annual review. Minor rewording in Criteria and Background sections with no impact on policy criteria. References reviewed and updated. |
CP.MP.81 | NICU Discharge Guidelines | Annual review. References reviewed and updated. |
CP.MP.86 | Neonatal Abstinence Syndrome Guidelines | Annual review. Updated description, criteria and background with equitable and inclusive language and no impact on criteria. References reviewed and updated. Reviewed by external specialist. |
CP.MP.85 | Neonatal Sepsis Management | Annual review. Reworded description with no clinical significance. Reworded criteria under I.A.2. "when meeting all of the following criteria" with no impact to criteria. Expanded criteria under I.A.2.a. and I.B.2.a. “Signs of neonatal sepsis (e.g.: hypotonia, lethargy, poor oral feeding, tachycardia, bradycardia, grunting, nasal flaring, cyanosis). Reworded criteria under II.D.1., II.D.3. and II.E. with no impact to criteria. References reviewed and updated. Reviewed by external specialist. |
WA.CP.MP.117 | Percutaneous Electrical and Peripheral Nerve Stimulation | Annual review. Added section II.D. to correspond to CP.MP.117. Coding reviewed and updated. References reviewed and updated. Updated description and background with no clinical significance. |
WA.CP.MP.526 | Stem Cell Therapy for Musculoskeletal Conditions | Annual review. References updated. Background updated to include HCA Billing Guidelines. |
WA.CP.MP.510 | Tinnitus Treatment | Annual review. References updated. Background updated to include HCA Billing Guidelines. |
V1.2024 | All Genetic Testing Policies | Twice-per-year review |
Policy Number | Policy Title | Revision Notes |
---|---|---|
CP.MP.107 | Durable Medical Equipment (DME) and Orthotics and Prosthetics Guidelines | Annual review. Updated description with no impact on criteria. Changed Orthopedic Care Equipment to Prosthetics and Orthotics Equipment. Table of contents updated. Retired pneumatic compression device criteria (E0675) for IQ. Updated "Cabinet style..." note under Ultraviolet panel lights. Under “Other Equipment” added code E0240 to “Specialized supply or equipment” section and added section, criteria, and coding (E1399, A9900) for “ROMTech device”. Reformatted Foot orthotics, custom criteria in “Prosthetics and Orthotics Equipment” section. Added criteria for Prosthetics and additions: Upper Extremity and Myoelectric in “Prosthetics and Orthotics Equipment” section. Added section, criteria, and coding (L8701, L8702) for “MyoPro Orthosis” under “Prosthetics and Orthotics Equipment”. Removed code L8035 from "other surgical supplies" and added section and criteria for "Breast Prosthetics" (L8030, L8035). Removed pediatric wheelchair codes (E1229, E1231, E1232, E1233, E1234, E1235, E1236, E1237, E1238, E1037) from manual wheelchair section. References reviewed, updated, and reformatted. Internal specialist review. |
Policy Number | Policy Title | Revision Notes |
---|---|---|
WA.CP.MP.525 | Catheter Ablation for Supraventricular Tachyarrhythmia | Annual review. References updated. Use of InterQual guidelines removed and policy updated to align with current HCA billing guidelines. CPT 93654 removed per billing guidelines. |
WA.CP.MP.500 | Mandibular Advancement Devices | Annual review. Reference reviewed |
CP.MP.38 | Ultrasound in Pregnancy | Updated Table 4 (Diagnosis Codes that Support Medical Necessity for First Detailed Fetal Ultrasound) to include the following codes and code ranges: A92.5, D56.0 through D56.9, D57.00 through D57.819, M32.0 through M32.9, M33.00 through M33.99, M34.0 through M34.9, M35.00 through M35.09, M35.1, M35.5, M35.8 through M35.9, M36.0, M36.8, N18.9, O00.01, O00.111 through O00.119, O00.211 through O00.219, O00.81, O00.91, O09.892 through O09.93, O10.012 through O10.019, O10.112 through O10.119, O10.212 through O10.219, O10.312 through O10.319, O10.412 through O10.419, O10.912 through O10.919, O11.2 through O11.3, O12.00, O12.02 through O12.03, O12.10, O12.12 through O12.13, O12.20, O12.22 through O12.23, O13.2 through O13.3, O13.5 through O13.9, O14.00, O14.02 through O14.03, O14.10, O14.12 through O14.13, O14.20, O14.22 through O14.23, O14.90, O14.92 through O14.93, O15.00, O15.02 through O15.03, O15.9, O16.2 through O16.3, O16.9, O22.50, O22.52 through O22.53, O23.00, O23.02 through O23.03, O24.414 through O24.415, O26.20, O26.22 through O26.23, O26.30, O26.32 through O26.33, O26.40, O26.42 through O26.43, O26.612 through O26.619, O26.832 through O26.839, O26.843 through O26.849, O26.852 through O26.859, O26.872 through O26.879, O28.5, O28.8 through O28.9, O29.012 through O29.019, O29.022 through O29.029, O29.112 through O29.119, O29.122 through O29.129, O29.212 through O29.219, O29.292 through O29.299, O30.90, O30.92 through O30.93, O31.30X1 through O31.30X9, O31.32X0 through O31.32X9, O31.33X0 through O31.33X9, O31.8X20 through O31.8X29, O31.8X30 through O31.8X39, O31.8X90 through O31.8X99, O32.0XX3 through O32.0XX9, O32.1XX1, O32.2XX1, O32.3XX1, O32.6XX1, O32.8XX1, O32.9XX1, O34.02 through O34.03, O34.30, O34.32 through O34.33, O36.20X0 through O36.20X9, O36.22X0 through O36.22X9, O36.23X0 through O36.23X9, O36.4XX0 through O36.4XX9, O36.60X0 through O36.60X9, O36.62X0 through O36.62X9, O36.63X0 through O36.63X9, O36.70X0 through O36.70X9, O36.72X0 through O36.72X9, O36.73X0 through O36.73X9, O36.80X0 through O36.80X9, O36.8130 through O36.8139, O36.8190 through O36.8199, O36.8220 through O36.8229, O36.8230 through O36.8239, O36.8290 through O36.8299, O36.8320 through O36.8329, O36.8330 through O36.8339, O36.8390 through O36.8399, O41.8X20 through O41.8X29, O41.8X30 through O41.8X39, O42.00, O42.012 through O42.02, O42.10, O42.112 through O42.119, O42.912 through O42.919, O43.012 through O43.019, O43.022 through O43.029, O43.112 through O43.119, O43.122 through O43.129, O43.212 through O43.219, O43.222 through O43.229, O43.232 through O43.239, O43.812 through O43.819, O44.00, O44.02 through O44.03, O44.10, O44.12 through O44.13, O44.20, O44.22 through O44.23, O44.30, O44.32 through O44.33, O44.40, O44.42 through O44.43, O44.50, O44.52 through O44.53, O45.002 through O45.009, O45.012 through O45.019, O45.022 through O45.029, O45.092 through O45.099, O46.002 through O46.009, O46.012 through O46.019, O46.022 through O46.029, O46.092 through O46.099, O46.8X2 through O46.8X9, O46.90, O46.92 through O46.93, O48.0 through O48.1, O60.00, O60.02 through O60.03, O60.10X0 through O60.10X9, O60.12X0 through O60.12X9, O60.13X0 through O60.13X9, O60.14X0 through O60.14X9, O98.012 through O98.019, O98.112 through O98.119, O98.919, O99.280, O99.282 through O99.283, O99.330, O99.332 through O99.333, O99.512 through O99.519, O9A.112 through O9A.119, U07.1, Z20.821, Z20.822, and Z21. References reviewed and updated. Internal specialist reviewed. |
WA.CP.MP.70 | Proton and Neutron Beam Therapies | Annual Review. Updated criteria I.G. to, unresectable benign or malignant central nervous system tumors to include but not limited to primary and variant forms of astrocytoma, glioblastoma, medulloblastoma, acoustic neuroma, craniopharyngioma, benign and atypical meningiomas, pineal gland tumors, and arteriovenous malformations. Added criteria I.H., Pituitary neoplasms. Restructured and added section A. and B. to criteria II. References reviewed and updated. |
CP.MP.142 | Urinary Incontinence Devices and Treatments | Annual review. Added note under Description to refer to CP.MP.133 Posterior Tibial Nerve Stimulation for Voiding Dysfunction for posterior tibial nerve stimulation treatment for urinary incontinence. Updated criteria I.B. from, urinary retention have been present for at least 12 months, to, urinary retention have been present for at least 6 months. Minor rewording in Criteria with no clinical significance. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist. |
CP.MP.151 | Transcatheter Closure of Patent Foramen Ovale | Annual review. Minor rewording in Background section with no impact on criteria. References reviewed and updated. |
CP.MP.180 | Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea | Annual review. Edits were made to criteria to align with the FDA updates issued June 8, 2023, for the Inspire Upper Airway Stimulation System. Updated criteria B. from "Age > 22 years" to "BMI ≤ 40 kg/m2"; changed C. from "BMI < 35 kg/m2" to "One of the following:" adding C.1 to C.3, indicating the updated age ranges and associated criteria. Contraindications were updated to I.D.a to I.D.g. The original criteria points I.E to I.I were removed. Background updated with no clinical significance. References reviewed and updated. Reviewed by external specialist. |
CP.MP.181 | Polymerase Chain Reaction Respiratory Viral Panel Testing | Updated description of Table 2 as Table 6 was removed. Added ICD-10 codes J15.61 and J15.69 to Table 4. Added ICD-10 codes J44.81 and J44.89 to Table 5. Deleted Table 6 from policy. |
CP.MP.206 | Skilled Nursing Facility Leveling | Retire |
CP.MP.247 | Transplant Service Documentation Requirements | Annual review. Minor rewording throughout Criteria with no impact on criteria. Criteria I.B.2. and Criteria I.B.3. updated to say “provider” instead of “physician.” Criteria I.B.5. updated to include documentation. C-peptide removed from Criteria I.B.5.e. Criteria I.B.5.f. updated to remove “no specific additional testing” and added documentation of failed total parenteral nutrition. Criteria I.B.10.g. updated to say rapid plasma reagin. Background updated with no impact on criteria. References reviewed and updated. Reviewed by internal specialist. |
Policy Number | Policy Title | Revision Notes |
---|---|---|
CP.BH.124 | ADHD Assessment and Treatment | Annual Review. Changed reference number for the policy from “CP.MP.124” to “CP.BH.124”. Added the following statement to section I and II: “It is the policy of Centene Advanced Behavioral Health and health plans affiliated with Centene Corporation”. In criteria point II. A. 1. replaced “Actometer” with “Actigraphy”. In criteria point I.A. 2. added “Acoustic reflex testing”. In criteria point I.A.12: removed Magnetic resonance imaging, brain functional MRI as it is already captured in I.A.16: under MRI. Removed I.A.14. “Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping”. In criteria point I.A.16. added “brain mapping” to the brain imaging section. In Criteria point I.A. 24 removed “Triiodothyronine T3 levels in the blood” and reworded as “Measures of thyroid hormones”. Removed II.A.18 “neuropsychological testing from the insufficient evidence list”, with corresponding codes also removed. In criteria point II. B.2., added “Application of modality (e.g. hot or cold packs, traction, mechanical, electrical stimulation (unattended), vasopneumatic devices, paraffin bath, whirlpool, diathermy (eg, microwave), infrared, ultraviolet, electrical stimulation (manual), iontophoresis, contrast baths, ultrasound, hubbard tank)”. Removed education interventions from criteria point II.B.19. and added policy statement III. “It is the policy of Centene Advanced Behavioral Health and health plans affiliated with Centene Corporation that interventions that are strictly educational in nature (e.g., classroom environmental manipulation, academic skills training training) are not medically necessary as they are not considered medical interventions”. Added criteria point II.B.19. “EndeavorRx®”. Replaced instances of dashes (-) with the word “to” within the CPT description code list. Coding reviewed. Added the following codes and related indications as not medically necessary when billed with a sole diagnosis of ADHD: 70496, 70554, 70555, 78610, 84436, 84437, 84439, 84442, 84443, 84445, 84478, 84479, 84481, 92568, 92569, 92570, 95954, 96020, 96902, 97010, 97012, 97014, 97016, 97018, 97022, 97024, 97026, 97028, 97032, 97033, 97034, 97035, 97036. References reviewed and updated. Policy reviewed by internal specialist. Policy reviewed by an external specialist. |
CP.MP.108 | Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-Thalassemia | Annual review. Added note at end of Description regarding criteria related to Zynteglo. Criterion I.C.3. removed related to lack of adequate support system. Expanded Criteria II.A. and Criteria II.B. to specify not in the context of gene therapy. Background updated with no impact on criteria. References reviewed and updated. Reviewed by internal and external specialist. |
WA.CP.MP.502 | Cochlear Implants | Annual review. References updated. Removed “Bilateral vs. Unilateral” from policy title. Removed use of InterQual criteria for unilateral implants as the HTA/HCA Billing Guideline covers unilateral and bilateral. Policy description edited to reflect unilateral and bilateral implants. Section I. removed “bilateral.” Section I. A. age parameters updated per Billing Guideline. Section I. C. minor grammatical error corrected with no impact on criteria. Policy note added per Billing Guideline that implantation may be performed unilaterally or bilaterally. Added note referencing CP.MP.14. |
CP.MP.31 | Cosmetic and Reconstructive Procedures | Annual review. Minor edits to I.A.4.b with no clinical significance. Updated pharmacy policies for Serostim (somatropin) in note. Removed CPT code 11310. References reviewed and updated. Reviewed by internal specialist. |
CP.MP.101 | Donor lymphocyte infusion | Annual review. Minor rewording in Description with no impact on criteria. Criteria II.B. updated to state grade 2 or higher acute graft versus host disease (GvHD). Background updated with no impact on criteria. References reviewed and updated. Reviewed by internal specialist. Updated policy description. Updated all criteria in statements I. and II. |
CP.MP.209 | GI Pathogen Nucleic Acid Detection Panel Testing | Annual review completed. Replaced previous criteria with current in sections I. and II. and removed section III. Background updated with no impact to criteria. Reworded some extraneous language with no clinical significance. Moved code 87506 from Table 1 to Table 2. Added Place of Service Code 19 in Table 3. Added Table 4, Table 5, and Table 6 to include ICD-10 diagnosis codes which support medical necessity. References reviewed and updated. |
CP.MP.250 | Lantidra (donislecel): Allogeneic pancreatic islet cellular therapy | New policy |
CP.MP.123 | Laser Therapy for Skin Conditions | Annual review. Added medically necessary indications I.C. atopic dermatitis and I.D. cutaneous T-cell lymphoma. Removed II.B. atopic dermatitis from insufficient evidence section. Added codes L20.81, L20.82, L20.89, C84.00 through C84.09, and C84.10 through C84.19 to table of ICD-10-CM diagnosis codes that support coverage criteria. References reviewed and updated. |
CP.MP.57 | Lung Transplantation | Revised adult and pediatric criteria to align with ISHLT 2021 consensus document. References reviewed and updated. |
CP.MP.202 | Orthognathic Surgery | Annual review. Added CPT codes 21248 and 21249. References reviewed and updated. |
CP.MP.109 | Panniculectomy | Annual Review. Combined criteria I.D. and E. into criteria I.D.1. and 2. Removed CPT code 00802 from policy. References reviewed and updated. Reviewed by external specialist. |
CP.MP.138 | Pediatric Heart Transplant | Annual review. Added additional criteria I.A.1.b.vi.a., pulmonary hypertension and a potential risk of developing fixed, irreversible elevation of pulmonary vascular resistance that could preclude orthotopic heart transplantation in the future. Updated I.D.1. from GFR < 40 mL/min/1.73m2 to GFR < 30 mL/min/1.73m2. Expanded I.D.2. with qualifying criteria for members who are HIV positive. Updated I.D.21. to exclude marijuana use when prescribed by a licensed practitioner and include required commitment to reducing substance use behaviors if urgent transplant timelines are present. Background reviewed and updated. References reviewed and updated. Reviewed by external specialist. |
CP.MP.246 | Pediatric Kidney Transplant | Annual review. Description updated to include source information for policy criteria. Updated Criteria I.A.1. from glomerular filtration rate (GFR) ≤ 15 mL/min/1.73m2 to GFR < 15 mL/min/1.73m2 to align with Kidney Disease: Improving Global Outcomes (KDIGO) guidance and Organ Procurement Transplant Network (OPTN) guidance. Updated Criteria I.A.2. to include members/enrollees with CKD stage 4 with GFR < 30 mL/min/1.73m2 who are expected to reach end stage renal disease (ESRD) to align with KDIGO guidance and OPTN guidance. Updated contraindications in I.B. consistent with KDIGO guidelines. References reviewed and updated. |
CP.MP.150 | Phototherapy for Neonatal Hyperbilirubinemia | Annual review. Reworded criteria I.C. for inclusive language. References reviewed and updated. |
CP.MP.181 | Polymerase Chain Reaction Respiratory Viral Panel Testing | Annual review. Replaced prior criteria in sections I. and II. with current criteria. Removed policy statement III. Background updated with no impact on criteria. Updated verbiage in Table 2 description to include new diagnosis code requirements. Added Place of Service Code 19 in Table 3. Added Table 4, Table 5, and Table 6 which include ICD-10 diagnosis codes. References reviewed and updated. |
CP.MP.98 | Urodynamic Testing | Annual review. Added criteria I.D.5. for 4.5. Prostate nodule, asymmetry or other suspicion of prostate cancer. Moved N40.3 from ICD-10 Table 2 to ICD-10 Table 1. References reviewed and updated. |
WA.CP.MP.527 | Vitamin D Testing | Annual review. Updated references. |
Policy Number | Policy Title | Revision Notes |
---|---|---|
CP.MP.129 | Fetal Surgery in Utero for Prenatally Diagnosed Malformations | Annual review. Criteria I.F.3. updated to include confirmation on fetal MRI. Added clarifying language to Criteria I.F.4. Background updated with no impact on criteria. Added CPT code 59072. ICD-10 codes removed. References reviewed and updated. Reviewed by external specialist.
|
WA.CP.MP.50 | Drugs of Abuse: Definitive Testing | Annual Review. Added an example of synthetic cannabinoids to I.A.1., drugs for which presumptive testing is not reliable. Coding reviewed. Replaced all instances of dashes (-) with the word “to” within the CPT and HCPCS codes. Added 0082U to the CPT codes that do not support coverage criteria list. Removed table of ICD-10 CM codes. Updated background information to include information regarding American Society of Addiction Medicine (ASAM). Other minor wording changes made to background with no clinical significance. References reviewed and updated. Policy reviewed by an internal specialist. Removed deleted codes 0143U, 0144U, 0145U, 0146U, 0147U, 0148U, 0149U, 0150U from table of CPT codes that do not support coverage criteria. |
Policy Number | Policy Title | Revision Notes |
---|---|---|
WA.CP.MP.519 | Administrative Days | Changed “denial” to “discharge” in Note.
|
CP.MP.100 | Allergy Testing and Therapy | Annual review. Updated description and background with no clinical significance. References reviewed and updated. Coding reviewed. Reviewed by external specialist. |
WA.CP.MP.37 | Bariatric Surgery | Modified section II.B. to allow family practice in addition to internal medicine physicians conduct pre-operative assessments. |
CP.MP.156 | Cardiac Biomarker Testing | Annual review. Background updated with no impact on criteria. Coding reviewed. References reviewed and updated. Reviewed by external specialist. |
CP.MP.105 | Digital EEG Spike Analysis | Annual review. Minor rewording in Criteria I. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist |
CP.MP.155 | EEG in the Evaluation of Headache | Annual review. Edits to policy name in header. Background updated with no clinical significance. References reviewed and updated. |
CP.MP.134 | Evoked Potential Testing | Annual review. References reviewed and updated. Reviewed by external specialist. |
CP.MP.153 | Helicobacter Pylori Serology Testing | Annual review. References reviewed and updated. Reviewed by external specialist. |
CP.MP.113 | Holter Monitors | Annual review. Criteria I. updated to specify a Food and Drug Administration (FDA) approved Holter monitor device, and age in Criteria I. changed from > 18 years old to ≥ 18 years old. Criteria I.D. updated to include arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy, or a first degree relative with HCM. Added Criteria I.O. for baseline or periodic screening for those with adult congenital heart disease. Criteria II. updated to specify an FDA approved Holter monitor device, and age in Criteria II. changed from ≤ 18 years old to < 18 years old. Minor rewording in background with no impact on criteria. References reviewed and updated. Reviewed by internal specialist. |
CP.MP.102 | Pancreas Transplantation | Added note to policy to see CP.MP.250 Lantidra (donislecel): Allogeneic Pancreatic Islet Cellular Therapy for criteria related to Lantidra. |
CP.MP.181 | Polymerase Chain Reaction Respiratory Viral Panel Testing | Removed note after the policy description referring to CP.CPC.03 Preventive Health and Clinical Practice Guidelines for PCR testing for COVID-19. Added 0202U, 0223U and 0225U to CPT table 2. |
CP.MP.154 | Thyroid Hormones and Insulin Testing in Pediatrics | Annual review. Edits to title in header. References reviewed and updated. Reviewed by external specialist. |
CP.MP.38 | Ultrasound in Pregnancy | Annual review. Minor rewording in Description, in Table 1 under Criteria IV., and in Criteria V. Verbiage added to indicate list is not all inclusive under Classifications of fetal ultrasounds Section I. and Section II. Background updated with no impact on criteria. Updated Table 4 Coding description. The following retired code ranges were removed: O35.0XX0 through O35.0XX9 and O35.1XX0 through O35.1XX9. The following code ranges were added: O35.00X0 through O35.00X9, O35.01X0 through O35.01X9, O35.02X0 through O35.02X9, O35.03X0 through O35.03X9, O35.04X0 through O35.04X9, O35.05X0 through O35.05X9, O35.06X0 through O35.06X9, O35.07X0 through O35.07X9, O35.08X0 through O35.08X9, O35.09X0 through O35.09X9, O35.10X0 through O35.10X9, O35.11X0 through O35.11X9, O35.12X0 through O35.12X9, O35.13X0 through O35.13X9, O35.14X0 through O35.14X9, O35.15X0 through O35.15X9, O35.19X0 through O35.19X9, O35.AXX0 through O35.AXX9, O35.BXX0 through O35.BXX9, O35.CXX0 through O35.CXX9, O35.DXX0 through O35.DXX9, O35.EXX0 through O35.EXX9, O35.FXX0 through O35.FXX9, O35.GXX0 through O35.GXX9, O35.HXX0 through O35.HXX9. References reviewed and updated. |